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INTRODUCTION 
 
Atopic dermatitis (AD) is a pruritic, chronic inflammatory skin disease with a wide 
variety of clinical features, which affects upto 20% of the population in some 
settings.(1,2) The etiology has been linked to complex interactions between the 
predisposing genes, the immune system and the environment.(1,3) 
 
AD is diagnosed based on various clinical criteria such as the Hanifin and Rajka 
criteria, Danish Allergy Research Centre Criteria, Schultz-Larsen criteria and the 
U.K. Working Party Diagnostic criteria.(4,5) The specificity of the criteria used in 
our study (The U.K. Working Party Diagnostic criteria) ranges from 90.4% to 98.3%  
and sensitivity from 10% to 95.5%.(4) 
 
The disease can cause impairment in the quality of life and the tools used to assess 
the same include Quality of Life Index (IDQOL) for children below 4 years of age(6), 
Children’s Dermatology Life Quality Index (CDLQI) for children between 4-16 years 
of age(6,7) and Dermatology Life Quality Index (DLQI) for those above 16 years.(8) 
The severity of AD is determined using several scoring systems, including SCORing 
Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI) and Patient 
Oriented Eczema Measure (POEM).(9) 
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There are several biomarkers used to assess the severity such as serum levels of 
thymus and activation-regulated chemokine (TARC), IL-18, lactate dehydrogenase 
(LDH), IgE and peripheral blood eosinophils.(10) Serum TARC levels was found to 
be the most reliable biomarker for AD as published in a meta-analysis in October 
2015.(11)  
 
Traditionally, the clinical disappearance of eczema and the subjective relief from 
pruritus have been considered as signs of remission. However, in most cases 
subclinical remnants persist and if the medical treatment is stopped before complete 
remission, chances of relapse are high.(12) Observing TARC levels is useful in 
improving adherence of the patients to the treatment regimens.(12,13)  There are no 
published studies in India assessing the correlation between serum TARC levels and 
AD and its severity. This study was undertaken to evaluate the clinical profile of 
patients with AD, study the serum levels of TARC in AD compared with controls and 
also the relationship with the clinical severity as assessed by SCORAD index. 
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AIMS AND OBJECTIVES 
 
Primary objective: 
1. To study the efficacy of thymus and activation-regulated chemokine as a 
diagnostic marker of atopic dermatitis and the association with the severity of 
the disease in the paediatric age group in the Indian context. 
2. To study the clinical profile of patients with atopic dermatitis.  
Secondary objectives: 
To study the quality of life of patients with atopic dermatitis and its correlation with 
serum TARC.  
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REVIEW OF LITERATURE 
 
Definition: 
AD is a pruritic, chronic relapsing inflammatory skin disease usually beginning in 
early childhood. Its rash is characterized by itchy papules, papulovesicles, erythema, 
excoriations and lichenification, which occur typically in a flexural distribution.(1) It 
is often associated with other atopic conditions in the person or his/her family 
members. Asthma develops in around 30% of children with AD and allergic rhinitis 
in 35%.(14) 
 
History: 
The earliest account of a possible AD dates back to as early as 69-140CE, as seen in 
the translation of the Roman historian Suetonius’s book, The Twelve Caesars, 
describing a cutaneous condition affecting Emperor Augustus, although there are 
even earlier descriptions of itchy skin conditions. The concept of ‘atopy’ was initially 
given in 1923 by Arthur Coca and Robert Cooke when an association between asthma 
and allergic rhinitis was recognized by them. It was explained with a term coined 
from the Greek word atopia in 1923 by Edward Perry, a professor of Greek at 
Columbia University, which means ‘strangeness’ or ‘out of place’. In 1933, Fred 
Wise and Marion Sulzberger introduced the term atopic dermatitis. Hanifin and Rajka 
published the first widely used criteria for diagnosing AD in 1980. Williams et al 
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modified the criteria in 1994 to develop the U.K. Working Party Diagnostic 
criteria.(15,16)  
 
Epidemiology: 
The prevalence of AD varies widely between different countries and can affect upto 
20% of children in some countries as determined in a multi-country cross-sectional 
study conducted by The International Study on Asthma and Allergies in Childhood 
(ISAAC) Steering Committee. In 6-7 year age-group, the lowest prevalence was 
found in Eastern Mediterranean and Indian subcontinent, while in the older age group 
of 13-14 years the highest prevalence was seen in Asia-Pacific, Eastern 
Mediterranean, Indian subcontinent and Northern and Eastern Europe. The Phase III 
of ISAAC study also shows that AD has plateaued in developed countries such as the 
United Kingdom and New Zealand but continues to increase in low-income 
countries.(2,17) The incidence is highest in infancy and childhood with 
approximately 60% of cases occurring within the first year of life and 90% within 5 
years of age.(18,19) 
 
Prevalence of AD in India: 
Prevalence studies from India are mostly hospital-based. In a hospital-based study in 
2012 conducted across 4 hospitals in India, one from each zone, the point prevalence 
was found to be 6.75% with the prevalence in South India being 2.8%.(20) In ISAAC 
phase III, current symptom of eczema was detected in 2.7% of participating children 
in the Indian subcontinent, severe eczema in 0.3% children and lifetime prevalence 
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of 4.4% in the age group of 6-7 years. The corresponding figures in the age group of 
13-14 years were 3.6%, 0.4% and 8.9%, respectively.(2,21)  
 
Etiopathogenesis of AD: 
Genetic, environmental and immunological factors are implicated in the pathogenesis 
of AD.(3) There is a complex interplay of the immune system with the epithelium, 
ultimately leading to disease manifestation.  
 
Genetic factors: 
The risk of developing the disease is increased with loss of function mutation in the 
gene encoding filaggrin (FLG), an epidermal peptide that plays an important role in 
maintaining the skin barrier.(22) Filaggrin is encoded on chromosome 1q21 within 
the epidermal differentiation complex (EDC).  
 
The risk is also influenced more by maternal disease status as compared to paternal 
status, though this is not universal.(23,24) The mechanisms underlying this 
observation could be genomic imprinting, mitochondrial transmission, interactions 
between the in utero environment and genes and exposure to the nutritional and 
immunologic properties of breast milk.(23) 
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Environmental factors: 
Climate:  
There are positive and negative correlations of AD symptoms with latitude and annual 
outdoor temperature, respectively. UV radiation, owing to its immunosuppressive 
effect, is an effective therapy for AD. There is a likely interplay of outdoor 
temperature, UV radiation, humidity and seasonal pollen counts in the pathogenesis 
of AD.(1) 
 
Urban vs rural living: 
The burden of AD is higher in urban areas.(1) 
 
Diet: 
ISAAC Phase 3 showed a protective effect of fresh fruit consumption, as opposed to 
fast food consumption. High fish intake during pregnancy and late infancy has also 
shown to confer a protective role, possibly due to the high content of anti-
inflammatory n-3 polyunsaturated fatty acids.(1,25)  
 
Breastfeeding and delayed weaning: 
The protective effect of breastfeeding in development of AD is controversial. A meta-
analysis of 27 study populations published in 2009 did not show any statistically 
significant benefit of exclusive breastfeeding until at least 3 months of age (pooled 
OR 0.89, 0.76-1.04).(26) However, an earlier meta-analysis in 2001 had shown a 
lower incidence of AD in children who were exclusively breastfed until 3 months of 
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life, especially those with a family history of atopy.(27) A recent multi-centre case-
control study in Italy showed lower risk of AD in children who were weaned early 
by 4-5 months of age as compared to those who were exclusively breastfed until 6 
months.(28) 
 
Obesity and physical exercise:  
It is unclear whether the association between obesity and AD is causal, e.g. secondary 
to inflammation mediated by adipokines like lectin; or related to the diet low in 
antioxidants such as fruits and vegetables, which can facilitate AD via oxidative stress 
pathways.(1) 
 
The hygiene hypothesis: 
Basic hygiene: 
The Avon Longitudinal Study of Parents and Children (ALSPAC) found a weak 
association between general hygiene measures and AD risk.(29) 
 
Day care: 
A cohort study in Denmark has found a reduction in risk of AD in children who attend 
day care centres, possibly related to increased microbial exposure. However, other 
studies have found an opposite effect.(30–32)  
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Farm environment: 
There is no convincing protective effect but consumption of unpasteurized milk and 
frequent contact with farm animals has reduced AD risk in some settings.(33) 
 
Pets: 
A meta-analysis showed protective effect of exposure to dogs whereas the picture 
was less clear for cats. (34) 
 
Endotoxin exposure: 
Endotoxins are lipopolysaccharides on the surface of gram-negative bacilli, which 
may be responsible for AD risk reduction with pet exposure. However, this effect was 
confined to high endotoxin exposure.(33,35)  
 
Helminth parasites: 
The relationship between helminths and human host depends on the type, burden and 
timing of the parasitic infection. Schistosoma and hookworms appear to be protective 
against atopy. The risk of AD later in life does not seem to increase on loss of 
helminth exposure, supporting that perinatal priming of the immune system can 
protect against AD.(33,36,37) There are studies, predominantly on animals, which 
suggest that parasites can induce a systemic immunoregulatory effect and regulate 
gut dendritic cells via Toll-like receptors, induce regulatory T-cells, B-cells, dendritic 
cells and anti-inflammatory cytokines, which may protect against allergic 
responses.(1) 
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Childhood vaccinations and antibiotics: 
There may be increased exposure to antigens of infectious agents through 
vaccinations, which can lead to Th2 immune response and increase the risk of allergic 
diseases. Antibiotics reduce the gut microflora and alter a child’s immune system 
with enhanced responses to environmental antigens.(1,33)  
 
Gut and skin microbiome: 
Some studies have shown more Staphylococcus aureus and coliforms with fewer 
bifidobacteria and lactobacilli in early gut microflora of people who later develop 
AD.(38,39) The gut microbiome is influenced positively by vaginal mode of delivery 
and having older siblings.(40) Skin microbiome also influences the cutaneous 
immune system. Staphylococcus aureus is a well-known cause of exacerbation and 
chronicity in AD.(1) 
 
Immune dysregulation: 
T helper 2 (Th2) cells seem to play a crucial role in pathogenesis of AD. Th2 
cytokines, IL-4 and IL-13, are increased in skin of early lesional AD, which also 
downregulate filaggrin expression.(1,41) In addition, IL-4 downregulates the 
expression of cutaneous defensins and increases the expression of bacterial adhesion 
molecules, which eventually facilitates colonization with Staphylococcus 
aureus.(1,42,43)  
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Increased levels of IL-5, GM-CSF, IL-12 and IFN-ˠ are found in chronic AD lesions. 
IL-5 and GM-CSF promote the survival and growth of eosinophils and macrophages. 
IL-12 plays an important role in polarization of Th1 cells producing IFN-ˠ, which 
induce apoptosis of keratinocytes associated with epidermal spongiosis. IL-22 is also 
found in high levels in chronic AD, which enhances keratinocyte proliferation, 
reduces antimicrobial protein expression and downregulates filaggrin expression. 
(1,44) 
 
AD dendritic cells have a high expression of FcεR1, a high-affinity IgE receptor, the 
stabilization on cell surface of which occurs by IgE binding. Its expression, therefore, 
correlates with total IgE.(45,46) 
 
Thymic stromal lymphopoietin (TSLP), a keratinocyte derived IL-7-like cytokine, 
causes direct neuronal triggering of itch and epidermal programming of dendritic 
cells to induce inflammatory Th2 cells. (47,48)  
 
There is a deficiency of Th17 in AD skin. However, the role of IL-17 is unclear. IL-
17A suppresses Th2 cytokines and TSLP expression, and IL-4 suppresses IL-17A 
function. This suggests that Th17 and Th2 pathways perhaps co-regulate each other. 
Interestingly, IL-17E (IL-25) enhances Th2 cell-mediated inflammation and 
downregulates filaggrin synthesis.(49) 
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Food allergy: 
Numerous dendritic cells expressing high-affinity IgE receptor are found on 
eczematous skin lesions. This enables the cells to take up a wider range of 
allergens.(49) This is thought to cause epicutaneous sensitization to environmental 
and food allergens in individuals with AD, which in turn may partly explain the 
relationship between food allergy, AD, allergic rhinitis and asthma, which define the 
‘atopic march’.(50) 
 
Allergic contact dermatitis: 
There is no evidence currently to suggest that AD may be a yet unidentified allergic 
contact dermatitis, though they share clinical and histological features.(1) A hospital-
based study in India observed that 7 patients with AD out of a total of 30 had co-
existent allergic contact dermatitis.(51) 
 
Autoimmunity: 
This could play a role as observed by IgE reactivity to several human protein antigens 
in patients with AD, which correlates with disease severity and chronicity. However, 
it is unclear whether autoimmunity is the primary disease mechanism or an 
epiphenomenon of chronic inflammation.(52)  
 
Sweating: 
Sweating induces itching in AD. This may be due to IgE-mediated allergic response 
to sweat components or an altered sensation with neuropeptides that are released in 
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the neurogenic control of sweat glands.(1,53) Eishi et al. showed that sweat 
production via direct cholinergic effect is almost similar between patients with AD 
and controls, but axon reflex-induced sweating was lower in volume and had a longer 
latency in AD.(54) 
 
Endocrine and psychological factors: 
Stress causes an increased production of cortisol. However, the rise has been found 
to be lower in those with AD.(55) Sex-steroids also probably play a role as seen in 
premenstrual flare or exacerbation or amelioration of eczema in pregnancy. They 
possibly modify sensitivity to the anti-inflammatory effects of 
glucocorticoids.(56,57) 
 
Pharmacological and vascular abnormalities: 
There is a tendency to vasoconstriction in small blood vessels in AD as seen by 
various responses such as white dermographism, delayed blanch with acetylcholine, 
white reaction with nicotinic acid esters, abnormal reaction to histamine, low finger 
temperature and pronounced vasoconstriction with cold exposure.(1,58) During 
elicitation of itch in AD and controls, the increase in histamine concentration is the 
same, but tryptase is significantly increased in AD. Tryptase activates PAR-2, 
increased in lesional AD skin.(59,60) 
 
Cyclic AMP (cAMP) is a key second messenger, the downstream effect of which 
includes increased anti-inflammatory cytokine, IL-10 production and decreased 
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expression of pro-inflammatory cytokine (TNF-α, IL-12) production in leukocytes. 
cAMP levels are increased by phosphodiesterase (PDE) inhibition. PDE4 inhibition 
mediates anti-inflammatory effects on various cell types including T lymphocytes, B 
lymphocytes, macrophages, monocytes, neutrophils and eosinophils.(61) 
 
Pathophysiology of pruritus: 
Non-histaminergic signaling is more relevant in AD. This can be mediated via PAR-
2, PAR-4, neuropeptides like substance P, calcitonin gene-related peptide (CGRP), 
somatostatin, vasoactive intestinal polypeptide (VIP), acetylocholine (Ach) in 
postganglionic sympathetic fibres and neuropeptide Y.(1) In vitro data has 
demonstrated the role of NFAT signaling in keratinocyte expression of TSLP.(47) In 
mouse model, it has been shown that selective ablation of lamina I neurons in spinal 
cord, expressing gastrin-releasing peptide receptor(GRPR), led to abolition of scratch 
behavior with multiple pruritogens.(62)  
 
Clinical features: 
AD has a wide range of clinical features, the cardinal ones being intense pruritus and 
cutaneous reactivity. Acute cutaneous lesions include intensely pruritic, 
erythematous papules which are associated with excoriations, vesicles and serous 
exudate. Subacute lesions include erythematous, excoriated scaling papules. Chronic 
lesions include thickened plaques, lichenification and fibrotic papules or prurigo 
nodularis. Other findings include Dennie-Morgan folds (accentuated grooves below 
the lower eyelid margin), darkening beneath the eyes, also referred to as allergic 
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shiners, facial pallor, cheilitis, pityriasis alba, white dermographism, atopic dirty neck 
(reticulate pigmentation on the sides of neck) and features suggestive of filaggrin 
mutation which include keratosis pilaris, ichthyosis vulgaris and hyperlinearity of 
palms and soles, especially over the thenar eminence.(63–65) Filaggrin mutations 
were found in 26.7% patients with AD and 14.4.% patients without AD in a study by 
Morar et al.(66)  
 
Hand eczema is another manifestation that may affect more than 50% of patients. 
Patchy vesicular and lichenified eczema can be seen in childhood. In more extensive 
disease, a diffuse, chronic lichenified eczema may be seen, which often persists into 
adult life. Erythroderma or exfoliative dermatitis involving more than 90% of the 
body surface area may be seen. Nail involvement may occur in the form of coarse 
pitting and ridging.(1,63) 
The distribution of lesions varies according to the age of the patient and disease 
activity. 
 
Infantile phase: 
The lesions usually start on the face and there is relative sparing of the napkin area. 
As the child starts crawling, the exposed surfaces such as the extensor aspect of the 
elbows and knees become involved.(1) Facial involvement was seen in 79% infants 
and 74.5% children in a study by Dhar et al(67), whereas it was seen in 25% patients 
in another study conducted by Sehgal et al.(68) 
 
 16 
 
Childhood phase: 
There is predominance of flexural eczema, especially the cubital and popliteal fossae 
from 18 to 24 months of age. Extensor distribution of eczema in this phase in 
uncommon but when present, may take longer time to remit.(1) 
 
Adult phase: 
Flexural inflammation is less problematic than facial and hand involvement. 
Involvement of the lip vermilion, nipple eczema and follicular lichenified papules 
may be seen. Photosensitivity may also occur.(1) 
 
Diagnosis and differential diagnosis: 
AD is diagnosed clinically based on the history, the morphology and distribution of 
lesions and other clinical signs. There are various formal set of criteria for the same 
such as the Hanifin and Rajka criteria, Danish Allergy Research Centre Criteria, 
Schultz-Larsen criteria and U.K. Working Party Diagnostic criteria.(5) The 
specificity of the U.K. Working Party Diagnostic criteria (Table 1) ranges from 
90.4% to 98.3%  and sensitivity from 10% to 95.5%.(4)  
 
A number of diseases can mimic AD such as inflammatory skin diseases like 
seborrheic dermatitis, contact dermatitis, psoriasis; infections and infestations like 
secondary syphilis, candidiasis, scabies and HIV/AIDS related skin changes.(69) 
There are also a group of relatively rare disorders with a rash similar to atopic eczema. 
These include hypereosinophilic syndrome, hyper-IgE syndrome, 
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agammaglobulinemia, anhidrotic ectodermal dysplasia, ataxia telangiectasia, 
phenylketonuria, Netherton syndrome and Wiskott-Aldrich syndrome.(1) 
 
Table 1. The U.K Working Party Diagnostic Criteria(70) 
Must have: 
An itchy skin condition (or parental report of scratching or rubbing in a child) 
 
Plus 3 or more of the following: 
1. History of involvement of the skin creases such as folds of elbows, behind the 
knees, fronts of ankles or around the neck (including cheeks in children under 10). 
2. A personal history of asthma or hay fever (or history of atopic disease in a first-
degree relative in children under 4). 
3. A history of a general dry skin in the last year. 
4. Visible flexural eczema (or eczema involving the cheeks/forehead and outer 
limbs in children under 4). 
5. Onset under the age of 2 (not used if child is under 4). 
 
 
Classification of severity: 
The severity of AD is determined using several scoring systems, including SCORAD, 
EASI and POEM. The EASI and SCORAD have been found to be the best available 
tools for assessing the disease severity.(9) The SCORAD index was developed by the 
European Task Force on Atopic Dermatitis in 1990 and consists of the an objective 
score which includes the extent and intensity of clinical features and a subjective 
score that includes sleep disturbance and pruritus.(70) The range of the objective 
SCORAD lies between 0 and 83 and the severity of AD can be classified as mild 
(<15), moderate (between 15 and 40) or severe (>40).(71,72) SCORAD index which 
includes the objective and subjective scores was similarly graded as mild (<25), 
moderate (25-50) and severe (>50).(73) In a systematic review which combined data 
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till October 2012, SCORAD was found to be a valid, internally consistent and 
interpretable composite score.(9) 
 
Complications and co-morbidities: 
Psychosocial aspects: 
The disease can cause impairment in the quality of life by causing sleep disturbance, 
teasing, social exclusion, depression and other behavioural disturbances. A recent 
study found an increased risk of mental health disorders in children with AD.(74) 
There are various tools that can be used to assess the quality of life, such as IDQOL 
for children below 4 years of age(6), CDLQI for children between 4-16 years of 
age(6,7) and DLQI for those above 16 years.(8) The quality of life indices can be 
scored from 0 to 30, with higher score indicating higher impact on the quality of life. 
In addition, IDQOL has a separate score for the severity of eczema, which correlates 
with the overall score.(75) Studies have shown a positive correlation between QOL 
indices and severity as assessed by three-item severity score(76) or SCORAD.(77) 
 
Growth delay: 
Children with AD have a growth delay, which may be attributed to the disease and 
also to the use of corticosteroid therapy.(78,79) 
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Secondary infections: 
Bacterial infections: 
Colonization and disease exacerbation by Staphylococcus aureus is common in AD. 
Secondary bacterial infections may also be caused by Streptococci.(1,80) 
 
Viral infections: 
When a virus which usually causes a localized or mild vesicular eruption causes a 
widespread eruption in patient with pre-existing dermatosis, it is referred to as 
Kaposi’s varicelliform eruption. Eczema herpeticum, an acute generalized infection 
caused by herpes simplex virus may develop in patients with AD. The patients may 
present with widespread lesions and high-grade fever, or the lesions may be localized 
to regions of pre-existing dermatitis. Eczema vaccinatum refers to a similar eruption 
caused by vaccinia virus. Coxsackie infection may also cause an abnormal 
response.(1) 
 
Various molecular mechanisms have been attributed to increased susceptibility for 
developing eczema herpeticum. Impaired mechanical skin barrier function involving 
both the stratum corneum and the tight junctions influenced by deficiency of claudin-
1 (CLDN-1), lower levels of antimicrobial peptides (AMPs) like defensins and the 
canthelicidin- LL-37, Th2 predominant milieu which further reduces the expression 
of AMPs and reduced plasmacytoid dendritic cells have been implicated.(81,82) 
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Ocular abnormalities: 
Dennie-Morgan folds, conjunctival irritation and keratoconjunctivitis have been seen 
in children with AD. Keratoconus or conical cornea is almost always bilateral and is 
considered to occur due to rubbing and use of topical steroids. Both posterior and 
anterior subcapsular cataracts occur. Retinal detachment has also been reported.(1) 
 
Lymphomas: 
The risk of lymphomas, both systemic and cutaneous, appears to be higher in severe 
AD but further studies are required to confirm the same. There is also insufficient 
evidence about the risk of lymphomas with the use of topical calcineurin 
inhibitors.(1) 
 
Investigations: 
The identification of factors triggering AD is predominantly clinical. Children who 
have a clear allergy-like reaction such as urticaria or acute abdominal symptoms may 
benefit from skin prick tests or IgE antibodies against the suspect food. However, in 
case of eczema, the reaction may be non-IgE mediated. Pus swabs for bacterial 
culture and sensitivity can identify colonization or infection by Staphylococcus 
aureus or β-haemolytic streptococci. Herpes simplex can be identified via a Tzanck 
smear, polymerase chain reaction (PCR), culture, immunofluorescence slide test or 
electron microscopy.(1) 
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The role of vitamin D is increasingly being recognized in immunomodulation in 
different disorders. It maintains the epidermal barrier probably through increased 
expression of filaggrin, involucrin and antimicrobial peptides. Current evidence 
suggests a beneficial effect of vitamin D on AD. However, the various studies are 
limited by a short study duration and a small sample size. (83,84) 
 
There are several biomarkers used to assess the severity such as serum levels of 
thymus and activation-regulated chemokine (TARC), IL-18, lactate dehydrogenase, 
IgE and peripheral blood eosinophils.(10)  
 
TARC: 
Thymus and activation-regulated chemokine (TARC/CCL17) is a Th2 chemokine. It 
is expressed in thymus constitutively and produced by keratinocytes, endothelial cells 
and monocyte-derived dendritic cells. It recruits cells expressing CCR4 and CCR8 
receptors and is involved in migration of Th2 cells. Its production by keratinocytes is 
upregulated by IL-1β and TNF-α. (85) Activation of PAR-2 (protease-activated 
receptor 2) by peptides also increases the transcription of TARC and therefore, 
proteases from mites may increase its levels via PAR-2.(86)  
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Figure 1. Speculated mechanism for abnormally high TARC in AD- vicious 
cycles of positive feedback (88) 
 
Studies have shown a higher TARC level in AD compared to healthy controls and 
patients with other skin diseases like chronic actinic dermatitis, pustular psoriasis, 
prurigo nodularis, mycosis fungoides, drug eruptions etc. (87,88) Serum TARC was 
also found to be the most reliable biomarker for assessing severity of AD as published 
in a meta-analysis in October 2015, wherein a strong correlation was found with the 
severity of the disease in 4 longitudinal and 16 cross-sectional studies mainly from 
Japan (pooled correlation coefficients of 0.60 and 0.64, respectively)(11) 
Traditionally, the clinical disappearance of eczema and the subjective relief from 
pruritus have been considered as signs of remission. However, in most cases 
subclinical remnants persist and if the medical treatment is stopped before complete 
remission, chances of relapse are high. (12) TARC levels have been found to decrease 
 23 
 
with treatment. (13,87) Observing TARC levels can, therefore, be useful in improving 
adherence of the patients to the treatment regimens.(12,13) 
 
The normal values of TARC differ based on the age of a person, with highest levels 
in infancy (Table 2).(89) This could be due to Th2-skewed responses seen towards 
the common environmental antigens in all newborns.(90) 
 
        Table 2. Normal TARC values 
Adult <450 pg/mL 
Infant 6–12 months <1367 pg/mL 
Infant 1–2 years <998 pg/mL 
Child 2–15 years <743 pg/mL 
 
Management: 
First line: 
Patient education, reduction of trigger factors, regular emollient applications and use 
of topical corticosteroids to induce remission constitute the first line treatment 
strategies. Oral antihistamines may be added for short periods. Oral antibiotics can 
be given if there is a secondary bacterial infection. Oral corticosteroids like 
prednisolone can be used to manage severe exacerbation of the disease. Its role, 
though limited, is definite in such cases.(1) 
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Proactive therapy with local application of potent topical steroids or topical 
calcineurin inhibitors to the healed areas twice a week can be used for 
maintenance.(91) 
 
Second line: 
The compliance of the patient must be assessed in those who fail to respond to 
treatment. The potency of topical corticosteroids may be increased or wet wrap 
technique may be used. Phototherapy using either ultraviolet B (UVB) or ultraviolet 
A (UVA) can be given. Narrow band UVB is preferred.(1) 
 
Third line: 
Cyclosporine: 
It suppresses the production of T-cells and IL-2. Cyclosporine significantly decreases 
disease activity within 2-6 weeks of initiation of treatment. The dose ranges from 3-
6mg/kg/day in two divided doses. Continuous long-term regimen, upto 1 year; or 
intermittent short-term courses of 3-6 months can be used.(92) 
 
Azathioprine: 
It is a purine analogue that inhibits DNA synthesis and can be used for treatment of 
refractory AD. The onset of action is slower as compared to cyclosporine and 
improvement in disease activity may be seen over first 3 months of use. The dose 
needs to be adjusted according to the patient’s ability to metabolise the drug, which 
in turn is determined by the activity of thiopurine methyltransferase (TPMT) enzyme. 
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TPMT levels in red blood cells should, therefore, be determined prior to initiation of 
azathioprine. The dose for patients with normal to high TPMT activity ranges from 
1-3mg/kg/day, whereas those with low TPMT activity should be given a dose of 0.5-
1mg/kg/day.(1,92) 
 
Methotrexate: 
It is an anti-folate metabolite that blocks the synthesis of DNA, RNA and purines and 
negatively affects the T-cell function. The average time to achieve maximal response 
is about 10 weeks.(92) 
 
Mycophenolate mofetil: 
It blocks purine synthesis by inhibiting inosine monophosphate dehydrogenase. The 
suggested dose in children ranges from 600-1200mg/ m2, which is equivalent to 40-
50mg/kg/day in case of young children and 30-40mg/kg/day in case of 
adolescents.(92) 
 
Interferon gamma (IFN-Ɣ): 
It is a cytokine that enhances natural killer cell production and increases macrophage 
oxidation. There are a few studies that show its efficacy in AD. There is no optimal 
dose recommended for AD but it is usually given thrice weekly as subcutaneous 
injections.(92) 
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Biological agents: 
The data for the use of tumour necrosis factor-α (TNF-α) inhibitors, theophylline, 
intravenous immunoglobulin (IVIg) for managing AD is currently insufficient. (92) 
 
Understanding the pathogenesis of AD has led to development of targeted therapies 
such as Dupilumab, which is a fully human monoclonal antibody against the α subunit 
of IL-4 receptor. It blocks IL-4 and IL-13 signalling, which are overexpressed in AD. 
It is given as a subcutaneous injection. Phase III trials have not identified significant 
safety concerns but further trials are required to establish long-term safety.(93) 
 
Lebrikizumab, a monoclonal antibody against IL-13, also showed good tolerance and 
significant improvement in moderate-to-severe AD in adults in a multicentre 
randomised phase II trial.(94) 
 
Crisaborole is a topical PDE-4 inhibitor, which can be used for treating mild to 
moderate AD.(95,96) Apremilast, an oral PDE-4 inhibitor has also been studied for 
treatment of AD but the results have not been as promising as in the case of 
psoriasis.(61) 
 
The role of probiotics in AD: 
A meta-analysis published in 2015 which included randomised trials administering 
probiotics to pregnant or nursing mothers or infants below the age of 3 months 
showed a benefit in preventing eczema in high-risk children. A mixture of 
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Lactobacilli and Bifidobacteria was effective rather than either strain alone.(97) 
Another meta-analysis showed a reduction in SCORAD in children between 1-18 
years of age who were given probiotic supplements. Lactobacillus, Lactobacillus 
fermentum and a probiotic mixture were effective. However, Lactobacillus 
rhamnosus strain GG and Lactobacillus plantarum showed no effect.(98)
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MATERIALS AND METHODS 
Study design: 
This was a hospital-based, case-control study of children with AD and those with 
disease mimicking AD attending a tertiary care centre. 
 
Setting: 
The study was done in the out-patient and inpatient departments, Department of 
Dermatology, Venereology and Leprosy, Christian Medical College, Vellore, a 
tertiary care hospital in Tamil Nadu. 
 
Period of study: 
19 months (December 2016–June 2018) 
 
Patient population: 
All patients (0-16 years of age) with AD, between the specified period, subject to 
fulfillment of the inclusion criteria were included.  Controls with diseases mimicking 
AD were included from the patients attending the Dermatology out-patient clinic.   
 
Cases: 
Inclusion criteria: 
1. Patients with AD diagnosed by UK Working Party Diagnostic Criteria 
2. Age < 16 years 
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3. Patients consenting for the study 
 
Exclusion criteria: 
1. Patients not willing to participate in the study 
2. Patients with age > 16 years 
 
Controls: 
Inclusion criteria: 
1. Patients with age < 16 years with any of the following diseases which are 
mimics of AD 
Inflammatory Skin diseases: 
i) seborrheic dermatitis 
ii) contact dermatitis 
iii) psoriasis 
Infections and infestations: 
i) candidiasis 
ii) scabies 
iii) impetigo 
 
Exclusion criteria: 
1. Age>16 years  
2. Not willing to participate in the study 
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Methodology: 
The diagnosis of AD was made based on the UK Working Party Diagnostic Criteria. 
All patients, who fulfilled the inclusion criteria for cases and controls, were recruited 
in the study after obtaining informed consent. (Annexure-1) 
The details pertaining to the study were recorded in a proforma as in Annexure 2. 
 
Demographic details: 
Demographic details regarding the age at presentation, gender and address were 
recorded. 
 
History pertaining to the AD: (Annexure 2) 
1. Antenatal and birth history were recorded. The birth order and duration of 
exclusive breastfeeding were also documented. 
2. The age and site of onset of AD and history of involvement of other sites were 
obtained. 
3. A history of dry skin or atopy were asked for. 
4. Details of triggering factors, including seasonal variation and relieving factors, if 
any were also taken. 
5. Details regarding complications such as cutaneous and systemic infections, 
behavioural changes or sleep disturbance were obtained. 
6. Family history of atopy was recorded. 
7. Necessary information regarding past treatment was also collected. 
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Clinical examination: (Annexure 2) 
1. The anthropometric measures such as height and weight were recorded. BMI 
was calculated for children 2 years or older if their weight was above the 97th 
centile. 
2. Presence of significant lymphadenopathy was documented. 
3. Any ocular changes, if present, were recorded. Screening for cataract was done 
with torchlight examination. 
4. The patient’s skin, scalp, nails and mucosae were examined. Presence of acute 
eczematous lesions (erythema, exudation, papules, vesiculopapules, scales or 
crusts) or chronic lesions (infiltrated erythema, lichenification, prurigo, scales or 
crusts) were recorded besides other features of AD. 
 
Severity of AD: 
The severity of the disease was assessed clinically using the SCORAD index 
(Annexure-3). The objective SCORAD ranges from 0-83 and subjective SCORAD 
from 0-20. SCORAD index was calculated by adding objective and subjective 
SCORAD. 
 
Laboratory parameters: 
Serum TARC levels were measured for all cases and controls using enzyme- linked 
immunosorbent assay (Abcam’s TARC Human ELISA kit). The minimum detectable 
dose of TARC was less than 5 pg/mL (Annexure-4). Normal TARC values decrease 
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with the age of the patient (89) and the published cut-off values were used for 
studying the correlation between different parameters in our study. 
 
Peripheral eosinophils, serum LDH, immunoglobulin E (IgE) and vitamin D were 
also measured for those who were willing for the same. The cut-offs for these 
investigations were based on the laboratory values used in our hospital. Atopy 
immunoblot was done in patients with history of food allergy who were willing for 
the same. 
 
Quality of life indices: 
The quality of life was assessed using IDQOL for children below 4 years of age and 
CDLQI for children between 4-16 years of age. Dermatitis severity was also assessed 
alongwith IDQOL for children aged under 4 years. (Annexure-5)  
  
Statistical methods: 
Sample size: 
Number of cases = 72 ~ 70.   Number of controls = 72 ~ 70. 
The sample size was calculated in the following way to show a sensitivity of serum 
TARC as 90% each for patients with mild AD and those with moderate to severe AD 
with a precision of  +10%. 
n 1 = 4 p q   
             d2 
p= 90% 
q=100-p= 100-90 = 10% 
 33 
 
d= +/- 10% 
 n1= 4 x 90 x 10 = 36 
  10x10 
 
n2 = 4 p’q’ 
             d2 
p’= 90% 
q’=100-p= 100-90 = 10% 
d= +/- 10% 
n2= 4 x 90 x 10 = 36 
  10x10 
 
n3 = n1+n2 
 where, 
n1= number of mild cases 
n2= number of moderate/severe cases 
n3= number of controls 
p = sensitivity of TARC for mild cases 
p’= sensitivity of TARC for moderate/severe cases 
d = precision 
 
Data analysis: 
Data was entered in EpiData version 3.1 and analysed using SPSS version 16.0. For 
continuous variables mean & standard deviation or median and interquartile range 
were used. For categorical variables numbers and percentages were used. Chi-square 
test was used to find the association between age groups and TARC levels. To assess 
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the relationship between TARC levels and other variables like SCORAD, peripheral 
eosinophils, LDH, IgE, correlation coefficient and unadjusted linear regression model 
were used. In unadjusted analysis, the significant variables at 0.05 level were 
considered in the adjusted analysis. 
 Receiver Operating Characteristic (ROC) curve was plotted and best cut-off for 
serum TARC was obtained. Sensitivity and specificity with 95% confidence interval 
and likelihood ratios were calculated.  
 
Funding: 
The study was funded by the Fluid research grant of CMC, Vellore 
 
Study approval: 
The study was approved by Institutional Review Board (Research and Ethics 
committee) [IRB no.  10320] (Annexure 6)
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RESULTS 
Number of out-patients in the Paediatric Dermatology clinic (December 
2016-June 2018) = 9901
CASES
Number of patients with atopic 
dermatitis screened = 119
No. of cases included 
in the study = 103
65 males, 38 females
No. of patients 
excluded=16
CONTROLS
Number of controls included 
= 70
38 males, 32 females
seborrheic dermatitis-
7
Contact dermatitis- 10
Scabies- 15
Impetigo- 15
Psoriasis- 23
No. of controls 
excluded = 4
Figure 2. Patient flow 
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A case-control study was conducted over a period of 19 months wherein 103 cases 
with AD and 70 controls with diseases mimicking AD were recruited. 16 cases and 
4 controls were excluded since they did not consent for investigations. 
 
Demographic profile: 
Cases: 
The age of children with AD varied from 0.13 to 16 years. The mean age and sex 
distribution of the cases is given in table 3. The distribution of male and female cases 
according to different age groups is shown in figure 3. 
Table 3. Age and sex distribution of cases 
 Atopic Dermatitis  
Gender Male Female Total 
Number 65 38 103 
Mean age (yrs) 5.78 6.55 6.06 
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Figure 3. Distribution of cases across different age groups 
The most common age groups were 5-8 years (n=39), followed by 0-4 years (n=38). 
There were more males than females in all age groups except 13-16 year group which 
had equal sex distribution. 
 
Geographical distribution: 
The highest proportion of the cases were from Tamil Nadu (33%) followed by West 
Bengal (23%). (Figure 4) 
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Figure 4. Geographical distribution of children with atopic dermatitis 
4, 4%
5, 5%
9, 9%
3, 3%
6, 6%
5, 5%
11, 10%
1, 1%
34, 33%
1, 1%
24, 23%
Andhra Pradesh/Telangana Assam
Bangladesh Bihar
Jharkhand Karnataka
Kerala Maharashtra
Tamil Nadu Tripura
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Controls: 
A total of 70 children with skin disease mimicking AD were recruited. Of these, 7, 
10, 15, 15 and 23 children had seborrheic dermatitis, contact dermatitis, scabies, 
impetigo and psoriasis, respectively. Their age ranged from 0.08 to 16 years. The age 
and sex distribution is shown in table 4. The gender distribution of controls in each 
disease category is given in table 5. 
 
Table 4. Age and sex distribution of controls 
Gender Male Female Total 
Number 38 32 70 
Mean age (yrs) 7.03 5.91 6.52 
 
The distribution of controls across various age groups is shown in figure 5. The 
highest number of controls were between 0 to 4 years of age. 
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Figure 5. Distribution of controls across different age groups 
 
Table 5. Distribution of controls by diagnosis 
Diagnosis No. of males No. of females Total 
Seborrheic dermatitis 4 3 7 
Contact dermatitis 6 4 10 
Scabies 10 5 15 
Impetigo 6 9 15 
Psoriasis 12 11 23 
 
 
Geographical distribution: 
The highest proportion of controls were from Tamil Nadu (50%) followed by West 
Bengal (19%). (Figure 6) 
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Figure 6. Geographical distribution of controls 
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Clinical history of patients with AD: 
Birth history: 
The number of children delivered by normal vaginal delivery and Caesarean section 
were 60 (58.3%) and 43 (41.7%), respectively. There were 59 (57.3%) first-born, 38 
(36.9%) second-born and 6 (5.8%) third-born children recruited in the study.  
 
There were 97 (94.2%) children who had been exclusively breastfed for a duration 
ranging from 15 days to a maximum of 2 years. The mean duration of exclusive 
breast-feeding was 5.8 + 3.5 months. 
 
Age of onset: 
There was a wide range of age on onset of symptoms of AD ranging from 0 to 108 
months, with a mean of 20.8 + 26.7 months. The onset of symptoms within first year 
of life was seen in 59 (57.3%) children and within the first 5 years of life in 92 
(89.3%) children. 
 
Sites of onset and involvement as per history: (Table 6) 
Face was the site of onset for 36.9% patients followed by cubital fossae (32%) and 
popliteal fossae (26.5%).  
 
Amongst the sites involved, 80.6% patients had facial involvement, followed by 
cubital fossae (79.6%) and popliteal fossae (74.8%). Of these 23.3% had more than 
1 site of involvement.  
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Table 6. Sites affected in AD 
Sites affected Frequency Percentage 
Face 83 80.6 
Neck 32.9 55.3 
Upper limb (Flexure) 82 79.6 
Upper limb (Extensor) 42 40.8 
Lower limb (Flexure) 77 74.8 
Lower limb (Extensor) 45 43.7 
Trunk 59 57.3 
Scalp 44 42.7 
Mucosa 2 1.9 
Nails 2 1.9 
 
 
 
Symptoms pertaining to the skin: 
Dryness of skin was reported by 94.2% of the cases.  
 
Symptoms of mucosal allergy: 
Mucosal allergy was present in 48 children (46.6%) out of whom 64.6% had 
asthma, 62.5% had allergic rhinitis and 20.8% had a history of allergic 
conjunctivitis. Figure 7 shows the number of children with each of the three 
conditions. 
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Figure 7. Personal history of mucosal allergy 
Triggers and relieving factors: 
Seasonal variation was noticed by parents in 68% of the patients, with a majority of 
them reporting exacerbation in the winter season (61.4%). A worsening of the skin 
condition in the summer season was seen in 41.4% of patients, followed by 8.7% and 
1.4% in the rainy and spring seasons, respectively. Exacerbation in 2 seasons was 
seen in 9 (8.7%) patients. 
 
Other triggers reported by parents included examination-related stress (2.9%), skin 
infections (1%), food allergens (36.9%), airborne allergens, including dust and 
cement exposure (17.5%), sweating (39.8%) and woollen clothing (32%). Amongst 
the 38 children who reported food triggers, atopy immunoblot testing was done in 23 
(60.5%) children and was positive in 15 (39.5%) of them. Habitual scratching was 
noticed as an aggravating factor in 6.8% patients. 
 
Bathing was reported as a relieving factor in 13 (12.6%) children, an air-conditioned 
environment in 4 (3.9%) children and distraction in 5 (4.9%) children. 
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Exposure to pets: 
Only 9 (8.74%) cases had exposure to domestic pets with equal number of cases being 
exposed to dogs (5, 55.56%) and cats (5, 55.56%). 1 patient was exposed to both dogs 
and cats. 
 
Treatment history: 
Of the 103 cases, 3 did not have previous treatment details and 12 children had not 
taken any dermatological treatment in the past. A total of 88 patients had taken some 
form of dermatological treatment, with 80.7% having used topical steroids and only 
21.6% topical calcineurin inhibitors. Amongst the systemic agents, 23, 5 and 2 
patients had used systemic steroids, cyclosporine and methotrexate, respectively. 
Phototherapy was given to 3 patients.  
 
Family history: 
A family history of atopy was present in 68 children, bronchial asthma being the 
most common (48, 46.6%) followed by allergic rhinitis (23, 22.3%). (Figure 8) 
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Figure 8. Family history of atopy 
 
Complications and comorbidities as per history: 
Sleep disturbance was present in 56.3% children and 12 cases (11.7%) also had 
behavioural disturbances owing to the disease, in the form of excessive irritability, 
anger or aggressiveness. 
 
A history of skin infections was present in 34 cases (33%), all of whom reported a 
bacterial infection. Of these, 20 (58.8%) patients had a history of recurrent infections. 
However, only 7 (20.6%) out of the 34 cases had a documented pus culture, all of 
which showed Staphylococcus aureus.  The bacterial swabs of 2 of these children 
also showed Klebsiella, Pseudomonas and non-fermenting gram negative bacilli. 
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None of the study patients had a history suggestive of eczema herpeticum or eczema 
vaccinatum. A small number of patients (7, 6.8%) also reported systemic infections 
in the form of respiratory infections (6) and post infectious glomerulonephritis (1). 
 
Two patients had Wiskott-Aldrich syndrome and one had anhidrotic ectodermal 
dysplasia. One patient had concomitant vitiligo.  
 
Clinical profile of cases: 
Anthropometry:  
Table 7 shows the distribution of height and weight percentiles across various age 
groups. Majority of the patients had height and weight between 3rd to 97th centile. 
There were 11.65% children with a height below the 3rd centile and 12.62% children 
with a weight below the 3rd centile. 
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Table 7. Height and Weight centiles 
 Height Weight 
 No. of cases Percentage No. of cases Percentage 
Below 3rd centile    
<1 yr 0 0 0 0 
1-2 yrs 2 13.33 2 13.33 
> 2 yrs 10 12.82 11 14.1 
 
Total 12 11.65 13 12.62 
3rd to 97th centile    
<1 yr 10 100 9 90 
1-2 yrs 10 66.67 13 86.67 
> 2yrs 61 78.21 58 74.36 
 
Total 81 78.64 80 77.67 
Above 97th centile    
< 1 yr 0 0 1 10 
1-2 yrs 3 20 0 0 
> 2 yrs 7 8.97 9 11.54 
 
Total 10 9.71 10 9.71 
< 1 yr (n=10), 1-2 yrs (n=15), >2 yrs (n=78) 
Of the 9 children whose weight was above the 97th centile, 2 (2.6%) children were 
overweight and 7 (8.9%) were obese based on the BMI centile for their age.  
 
Cutaneous features:  
The various morphological types seen in our patients are presented in table 8 and 
the distribution in table 9.  
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Table 8. Morphology of lesions in infantile and childhood AD 
Feature Infantile AD (n=15) Childhood AD (n=88) p 
values  Number Percentage Number Percentage 
Acute eczema 14 93.3 56 63.6 <0.001 
Follicular 
eczema 
2 13.3 2 2.3 0.065 
Erythroderma 1 6.7 5 5.7 0.880 
Lichenification 4 26.7 52 59.1 0.068 
Prurigo - - 2 2.3 - 
Psoriasiform - - 3 3.4 - 
p value for chronic lesions (lichenification+prurigo+psoriasiform) = 0.042 
The significant values are highlighted in bold.  
 
Patients were categorized into infantile AD (< 18 months) and childhood AD (> 18 
months).(1) 
Infantile AD:  
Amongst the children under 18 months of age (n=15), acute eczematous lesions were 
the most common morphological type seen in 14 (93.3%) cases. Localized lesions 
were present in 3 (20%) children, all of whom had lesions over the face. Extensor 
distribution of lesions was seen in 7 children of whom it was the only site involved 
in 2 (13.3%). 5 (33.3%) patients had involvement of the cubital fossae and 6 (40%) 
had involvement of the popliteal fossae. Both flexural and extensor involvement was 
seen in 5 (33.3%) cases. Overall, involvement of the face, trunk and extensor aspect 
of extremities was more common in the infantile phase as compared to the childhood 
phase. (Table 9) Erythroderma was seen in 1 (6.7%) case. 
Chronic lesions in the form of lichenification were seen in 4 (26.7%) cases, all of 
whom also had features of acute eczema. Extensor involvement was seen in 3 (20%) 
cases. Flexural involvement was seen in only 1 (6.7%) case. 
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Table 9. Distribution of lesions in infantile phase & childhood phase 
 Infantile AD (n=15) Childhood AD (n=88) 
 Acute 
eczematous 
lesions 
Chronic 
lesions 
Acute 
eczematous 
lesions 
Chronic lesions 
(Lichenification/ 
Prurigo/Psoriasiform*) 
Sites 
affected 
No. 
of 
cases 
% of 
cases 
No. 
of 
cases 
% of 
cases 
No. 
of 
cases 
% of 
cases 
No. of 
cases 
% of cases 
Face 13 86.7 1 6.7 34 38.6 9 10.2 
Neck 5 33.3 1 6.7 20 22.7 18 20.5 
Cubital 
fossa 
5 33.3 0 0 34 38.6 41 46.6 
Popliteal 
fossa 
6 40.0 1 6.7 36 40.9 38 43.2 
Axilla 2 13.3 0 0 11 12.5 0 0 
Extensor 
of upper 
limb 
7 46.7 3 20.0 22 25.0 16 18.2 
Extensor 
of lower 
limb 
6 40.0 3 20.2 24 27.3 20 22.7 
Trunk 9 60.0 1 6.7 24 27.3 9 10.2 
*Prurigo in 2 patients involving extensor aspects of upper & lower limbs in both and trunk & 
flexor aspect of lower limb in 1. 
 
Childhood AD:   
Amongst children above 18 months of age (n= 88), acute eczematous lesions were 
most common, similar to the infantile phase, seen in 56 (63.6%) cases. (Table 8) 
Localized lesions were present in 9 (10.2%) children with 6 (6.8%) having 
involvement of the face and 1(1.1%) each having involvement of the cubital fossae 
and extensor aspect of upper and lower limbs, respectively. Ear lobe involvement was 
seen in 2 (2.3%) children. Cubital fossae were involved in 34 (38.6%) cases and 
popliteal fossae in 36 (40.9%) cases. Extensor distribution alone was seen in 5 (5.7%) 
children with 3 (3.4%) children having both upper and lower limb involvement. Both 
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flexural and extensor involvement was seen in 27 (30.7%) children. Erythroderma 
was seen in 5 patients.  
 
Chronic lesions in the form of lichenification were seen in 52 (59.1%) children,  
prurigo in 2 (2.3%) children and psoriasiform lesions in 3 (3.4%) children. 
Psoriasiform lesions involved the extensor aspect of upper and lower limbs in all of 
them, face in 2 (2.3%) children and trunk in 1 (1.1%) child. Among these, 24 (27.3%) 
had only lesions of chronic AD and the rest had features of both acute and chronic. 
Overall, localized lesions of chronic AD were seen in 11 (12.5%) children with 
involvement of the face, cubital fossae, flexor and extensor aspects of the lower limbs 
in 3 (3.4%), 6 (6.8%), 1 (1.1%) and 1 (1.1%) cases, respectively. Flexural 
involvement was seen in 47 (53.4%) children. Extensor involvement was seen in 22 
(25.0%) children.  
 
Overall, acute eczema was more common in infants as compared to children and 
chronic lesions were more common in children, both being statistically significant (p 
value of <0.001 and 0.042, respectively). (Table 8) Chronic lesions in the flexural 
aspects of extremities were more common in childhood phase as compared to the 
infantile phase, though not statistically significant (p value- 0.032). (Table 9) 
 
Other cutaneous features: 
Dennie-Morgan folds were observed in 20 (19.4%) patients. Xerosis was seen in 88 
(85.4%) patients.  
 52 
 
 
Clinical features suggestive of filaggrin mutation such as palmar hyperlinearity, 
keratosis pilaris and ichthyosis vulgaris were seen in 71 (68.9%), 24 (23.3%) and 20 
(19.4%) patients, respectively. All 3 features were seen in 10 (9.7%) cases and any 2 
of the 3 features in 29 (28.2%) cases.  
 
Follicular prominence was seen in 9 (8.7%) patients. Excoriations were observed in 
61 (59.2%) children. Nipple eczema was not seen in any of our patients. 
 
Other findings: 
Nail changes were seen in the form of transverse or longitudinal ridges, Beau’s lines, 
leukonychia and perionychial papules in 5 children. Cheilitis was present in 2 (1.9%) 
patients. 
 
Lymphadenopathy: 
Lymphadenopathy was present in 22 (21.4%) children with cervical, axillary and 
inguinal lymphadenopathy in 16.5%, 4.9% and 4.9%, respectively. More than 1 
lymph node group was involved in 5 (4.9%) children. 
 
Complications at the time of induction into the study: 
A height below the 3rd centile was seen in 11.6% (12) cases and weight below the 3rd 
centile in 12.6% (13) children.  
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A minority of the patients had ocular changes, with 1 patient each with amblyopia, 
blepharitis, watering, redness, refractory error and squint. Children were not sent for 
routine ophthalmological screening in this study. 
 
Four (3.9%) patients also had acanthosis nigricans and all of them were obese (BMI 
above 95th centile). 
 
Secondary bacterial infection of the skin was seen in 18 (17.5%) patients, with 7 
having a documented Staphylococcal infection. Other organisms isolated from pus 
cultures included beta-hemolytic Streptococcus (2), Klebsiella (2), Pseudomonas (1) 
and non-fermenting gram negative bacilli (1).  Nasal swab was done in 28 (27.2%) 
children, out of which 22 (78.6%) children showed Staphylococcal carriage. 
 
Laboratory parameters and biomarkers: 
The laboratory parameters which have been previously shown to correlate with 
disease severity were done for those willing and the results are as follows: 
Eosinophilia: 
Peripheral eosinophilia, as defined by peripheral eosinophils above 6%, was present 
in 56 (54.4%) patients out of all 103 patients for whom it was done. The values ranged 
from 0 to 31%. The mean peripheral eosinophils in different age groups is shown in 
table 10 and the number of children with elevated eosinophils is shown in figure 9. 
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Table 10. Peripheral eosinophilia in different age groups 
Age group 
(years) 
Mean peripheral 
eosinophils (%) 
0-4 8.18+6.28 
5-8 8.69+5.86 
9-12 8.35+6.36 
13-16 10.33+6.62 
Total 8.53+6.09 
 
 
 
Figure 9. Distribution of eosinophilia across different age groups 
The highest number of cases with eosinophilia was found in the age group of 5 to 8 
years. 
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LDH: 
LDH levels were done for 89 cases and was elevated (>460 units/L) in 76 (85.4%) 
patients (range- 359 to 1320 units/L). The mean LDH in different age groups is shown 
in table 11 and the number of children with elevated values is shown in figure 10. 
 
Table 11. Mean LDH for different age groups 
Age groups (years) Mean LDH (units/L) 
0-4 699.12+143.14 
5-8 643.26+223.91 
9-12 576.33+174.45 
13-16 660.00+299.26 
Total 654.45+195.64 
 
 
 
Figure 10. Distribution of normal and elevated LDH across different age 
groups 
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The highest number of cases with elevated LDH was found in 0-4 year age group. 
 
Serum IgE: 
Serum IgE ranged from 1.5 to 15,488 units/mL and was elevated in 82 (85.4%) out 
of 96 patients for whom it was done, based on the age specific cut-offs (0-1 yr: 1-29 
units/mL; 1-3 yrs: 1-49 units/mL and above 3 yrs: 5-100 units/mL). The number of 
children with normal and elevated IgE is shown in figure 11. 
 
 
Figure 11. Distribution of normal and elevated IgE across different age groups 
 
The highest number of cases with elevated IgE was found in 5-8 year age group. 
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Vitamin D: 
Hypovitaminosis D was present in 62 (92.5%) out of the 67 children for whom it was 
measured. The mean vitamin D level was 17.36 + 8.54 ng/mL, which was below 
normal of 30.0 ng/mL. It also correlated inversely with SCORAD index (r= -0.13) 
which was statistically not significant (p value- 0.29). There was no significant 
correlation between vitamin D and TARC values in the age groups of 1-2 years (n=7, 
r= -0.18, p value= 0.70) and above 2 years (n=58, r= 0.06, p value = 0.64). The 
correlation was not assessed for children below 1 year of age since vitamin D was 
tested in only 2 infants.  
 
TARC: 
As the published values of TARC levels (89) are available for age groups of less than 
1 year, 1-2 years and above 2 years, all patients were classified into these age groups 
to assess the relationship with other parameters. 
TARC values in cases ranged from 14pg/mL to 2503pg/mL with a mean of 862.83 + 
782.19.  
Age specific mean TARC values and the range of values are recorded in table 12.  
Table 12. Mean TARC values in different age groups of cases 
Age group 
Normal TARC(89) 
(pg/mL) 
Mean TARC 
(pg/mL) 
Median 
(pg/mL) 
Range 
(pg/mL) 
< 1 yr (n=10) < 1367 1,186.90 993.50 372-2500 
1-2 yr (n=15) < 998 814.40 703.00 170-2500 
>2 yrs (n=78) < 743 830.60 467.50 14-2503 
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It was elevated in 33 (32%) cases based on the existing cut-off values (89), with the 
highest proportion in those above 2 years (27, 81.8%) (Figure 12) 
 
Figure 12. Distribution of normal and elevated TARC in AD 
TARC values in controls ranged from 46 pg/mL to 2500 pg/mL with a mean of 531.53 
+ 491.21. It was within the normal range in 60 (85.7%) controls. (Table 13) 
Table 13. Distribution of serum TARC levels in controls 
Diagnosis Mean TARC 
(pg/mL) 
Range of 
TARC 
(pg/mL) 
No. with 
normal 
TARC 
No. with 
elevated 
TARC 
% with 
elevated 
TARC 
Seborrheic 
dermatitis 
669.86+685.02 107-1,841 5 2 28.57 
Contact 
dermatitis 
625.50+344.14 313-1,129 9 1 10 
Scabies 561.80+512.28 108-1,646 13 2 13.33 
Impetigo 572+383.80 181-1,683 14 1 6.67 
Psoriasis 402.61+538.90 46-2,500 19 4 17.39 
Total 531.53+491.21 46-2,500 60 10 14.29 
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Seborrheic dermatitis (2/7 patients) and psoriasis (4/23 patients) were associated with 
elevated TARC levels. The highest serum TARC level was seen in a patient with 
psoriasis. (Table 19) The patient was not known to have an atopic diathesis. 
 
The mean and median TARC values for cases and controls in different age groups is 
shown in table 14.  
Table 14. Mean and median TARC values amongst cases and controls 
Age group Cases Controls 
Mean 
(pg/mL) 
Median Mean Median 
<1 yr (n=10) 1,186.90 993.50 1,064.80 1,117.50 
1-2 yrs (n=15) 814.40 703.00 531.17 532.50 
>2 yrs (n=78) 830.60 467.50 420.52 249.50 
 
 
The difference between the median TARC values amongst the cases and controls was 
statistically significant (p value= 0.004). 
 
The median TARC level was lower in patients on systemic therapy (390 pg/mL) 
compared to the other cases (469 pg/mL) (p value = 0.04) 
 
Sensitivity and specificity of serum TARC: 
Since the number of children under 1 year and between 1-2 years were few, ROC 
curves were not drawn for them. 
 
ROC curve for serum TARC levels for those above 2 yrs of age (after excluding an 
outlier with TARC value of 2500 pg/mL) is as shown in figure 13. 
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Figure 13. ROC curve for children above 2 years 
In our study, the optimal cut-off level for TARC for the diagnosis of AD in children 
above 2 years was 365 pg/mL with a sensitivity of 57.7% and specificity of 72.3%. 
The positive predictive value was 77.6% (C.I- 64.7% to 87.5%) and negative 
predictive value was 50.8% (C.I- 38.2% to 63.2%). Using this value, the number of 
patients with TARC levels of > 365 pg/mL was 46. 
 
Table 15 shows the relationship between TARC levels and SCORAD, QOL indices 
and other biomarkers. 
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Table 15. Pearson correlation coefficient(r) between serum TARC levels 
and SCORAD, QOL indices and other biomarkers 
Parameter < 1 yr 1-2 Yrs >2 yrs 
 r p value r p value r p value 
1. Objective           
…SCORAD 
0.353 0.317 -0.176 0.530 0.524 <0.001 
2. SCORAD 
index 
0.320 0.367 -0.230 0.410 0.538 <0.001 
3. Peripheral 
eosinophils 
-
0.083 
0.819 0.162 0.565 0.583 <0.001 
4. LDH -
0.549 
0.100 0.440 0.133 0.550 <0.001 
5. IgE 0.510 0.161 0.094 0.759 0.169 0.150 
6. IDQOL 0.391 0.263 -0.190 0.497 0.823 0.003 
7. CDLQI NA  NA  0.380 0.001 
The significant correlations are highlighted in bold. (p value < 0.05) 
NA- not applicable 
 
There was a statistically significant correlation of serum TARC levels with objective 
SCORAD, SCORAD index, peripheral eosinophils, LDH, IDQOL and CLDQI in 
children above 2 years of age. 
 
The increase in the levels of serum TARC with rise in SCORAD indices (mild <25, 
moderate 25-50, and severe >50) is shown in figure 14. 
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Figure 14. TARC values with SCORAD index 
 
TARC values vs mucosa allergy 
There was no statistically significant difference in serum TARC values amongst 
those with or without a history of atopy. 
 
TARC values vs phenotypic features of filaggrin mutation 
The correlation between serum TARC levels in children older than 2 years and 
phenotypic features of filaggrin mutation were studied. The TARC levels in those 
with (mean TARC 241.67 + 194.57 pg/mL) and without (mean TARC 907.42 +  
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812.19 pg/mL) all 3 features of filaggrin mutation (n=10, 9.7%) were significant (p 
value= 0.003) with higher TARC values in those without the mutation. No significant 
difference was found when only 2 of the 3 features were present.  
 
Severity scoring: 
The mean objective SCORAD was 28.9 + 18.3 with the lowest and highest scores of 
1.6 and 75.6, respectively (Objective SCORAD, minimum-0, maximum-83). The 
mean subjective SCORAD was 8.3 + 5.2 (Subjective SCORAD, minimum-0, 
maximum-20). The highest SCORAD was seen in the age group of 9-12 years, 
followed by 13-16 years. (Table 16) 
Table 16. Age-wise distribution of mean SCORAD 
Age group 
(years) 
Mean objective SCORAD Mean SCORAD index 
(Objective + Subjective) 
0-4 28.8 36.0 
5-8 27.6 36.4 
9-12 31.5 41.0 
13-16 30.0 37.0 
 
 
The correlation coefficient between objective SCORAD or SCORAD index and 
serum TARC levels, peripheral eosinophils, LDH, IgE and quality of life scores are 
given in tables 13 and 14.  
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Table 17. Pearson correlation coefficient(r) between objective SCORAD & 
SCORAD index and other clinical and laboratory parameters 
  Objective SCORAD 
Parameter  < 1 yr (n=10) 1-2 yrs 
(n=15) 
>2 yrs (n=78) 
  r p value r  p value r p value 
TARC  0.353 0.317 -0.176 0.530 0.524 <0.001 
Peripheral 
eosinophils 
 0.569 0.086 0.595 0.019 0.368 .001 
LDH  -0.445 0.198 0.091 0.767 0.546 <0.001 
IgE  0.423 0.257 -0.135 0.660 0.306 0.008 
IDQOL  0.515 0.128 0.227 0.415 0.882 0.001 
CDLQI  NA* 0.480 <0.001 
The significant correlations are highlighted in bold. (p value < 0.05) 
*NA-not applicable for age < 4 yrs 
 
 
Table 18. Pearson correlation coefficient(r) between SCORAD index and other 
clinical and laboratory parameters 
 SCORAD index 
Parameter <1yr (n=10) 1-2yrs (n=15) >2yrs (n=78) 
 r p value r p value r p value 
TARC 0.320 0.367 -0.230 0.410 0.538 <0.001 
Peripheral 
eosinophils 
0.578 0.080 0.609 0.016 0.397 <0.001 
LDH -0.434 0.221 0.067 0.828 0.582 <0.001 
IgE 0.490 0.181 -0.046 0.881 0.331 0.004 
IDQOL 0.622 0.055 0.362 0.185 0.926 <0.001 
CDLQI NA 0.541 <0.001 
The significant correlations are highlighted in bold (p value < 0.05) 
*NA- not applicable for age < 4 yrs 
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As seen in the above tables, the following investigations had a significant positive 
correlation with objective SCORAD and SCORAD index: 
• 1-2 year age group: Peripheral eosinophils 
• Above 2 years: Serum TARC, peripheral eosinophils, LDH and IgE; with 
highest correlation with serum LDH, followed by serum TARC. 
Quality of life indices also correlated significantly with SCORAD in children above 
2 years of age. 
 
Quality of life indices: 
Quality of life for 35 children, who were below 4 years of age was assessed using 
IDQOL (minimum and maximum IDQOL score of 0 and 30, respectively and 
dermatitis severity score of 0 and 4, respectively). The mean score was 9.4 + 5.84, 
ranging from a score of 1 to 27. The mean of IDQOL and dermatitis severity in 
different age groups is presented in Table 19. 
Table 19. Mean IDQOL and dermatitis severity 
Age (in years) Mean IDQOL Mean Dermatitis Severity score 
< 1 yr (n=10) 8.4 2.3 
1-2 yrs (n=15) 9.3 2.3 
>2 yrs (n=10) 10.6 2.2 
Total 9.4 2.3 
 
 
The correlation coefficients and p values of various laboratory markers with IDQOL 
are presented in table 20.  
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Table 20. Pearson correlation coefficient between IDQOL and laboratory 
markers 
Parameter < 1 yr 1-2 yrs >2 yrs 
 r p value r p value r p value 
TARC 0.391 0.263 -0.190 0.497 0.823 0.003 
Peripheral 
eosinophils 
0.527 0.117 0.513 0.050 0.682 0.030 
LDH -0.571 0.085 0.006 0.984 0.583 0.100 
IgE 0.760 0.018 0.050 0.871 0.308 0.386 
The significant values are highlighted in bold (p value < 0.05) 
 
There was a significant correlation between IDQOL and serum TARC levels & 
peripheral eosinophils in children above 2 years. There was also a significant 
correlation of IDQOL with IgE in children below 1 year of age. 
 
CDLQI was done to assess the quality of life of children who were 4 years of age or 
older (CDLQI, minimum and maximum scores of 0 and 30, respectively). The mean 
CDLQI score was 12.5 + 7.2, ranging from 0 to 27. Its correlation with laboratory 
parameters is given in table 21. 
 
Table 21. Correlation between CDLQI and laboratory parameters 
Parameter Age 4-16 yrs 
 r p value 
TARC 0.380 0.001 
Peripheral eosinophils 0.414 <0.001 
LDH 0.363 0.006 
IgE 0.234 0.062 
The significant values are highlighted in bold (p value < 0.05) 
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There was a significant correlation of CDLQI with serum TARC levels, peripheral 
eosinophils and serum LDH. 
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Figure 15. Eczema on cheeks in an (A) infant and (B) child 
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Figure 16. Follicular eczema 
 
Figure 17. Involvement of the scalp in a child with AD 
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A. Centrofacial sparing 
 
 
 
 
 B
 
Figure 18. Erythroderma secondary to AD 
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Figure 19. Flexural lichenification in a child with AD 
 
 
Figure 20. Psoriasiform lesions 
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A   
 B 
 C 
Figure 21. Features of filaggrin mutation: (A) Palmar hyperlinearity  
(B) Keratosis pilaris (C) Ichthyosis vulgaris 
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A)  
Mild AD: 
SCORAD 
index = 13.6 
 
B) 
Moderate AD: 
SCORAD 
index = 43.5 
 74 
 
 
 
C) 
Severe AD: 
SCORAD 
index = 50.5 
 
Figure 22 . Mild (A), moderate (B) and severe (C) AD 
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A 
 
B 
Figure 23. Complications in AD: (A) Secondary bacterial infection  
(B) Acanthosis nigricans in a child with obesity 
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A 
B 
Figure 24. Mimics of AD: (A) Seborrheic dermatitis (B) Psoriasis 
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Figure 25. Scabies
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DISCUSSION 
 
AD is a chronic relapsing pruritic condition, which usually starts in childhood. It 
presents with a wide variety of clinical features.(1) The ISAAC committee noted a 
wide variation in the prevalence of AD across countries. (2) Various biomarkers have 
been studied to assess the severity such as serum levels of TARC, IL-18, LDH, IgE 
and peripheral blood eosinophils.(10) There are several studies on the demographic 
and clinical profile of AD from India in the paediatric age group (67,68) however, 
there are no Indian studies assessing the efficacy of TARC to predict the diagnosis or 
severity of the disease. Serum TARC was found to be the most reliable biomarker for 
AD according to a meta-analysis published in October 2015.(11)  
 
In this study, in addition to the clinical profile of AD in the paediatric age group, we 
evaluated the efficacy of TARC as a diagnostic marker and for assessment of disease 
severity in the Indian subcontinent using a case-control design. Quality of life 
impairment was also studied.  
 
The demographic details of our study were compared with that of previous studies 
published on AD and are shown in table 22. 
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Table 22. Comparative profile of the demographic and clinical data between 
the present study versus previous studies 
Parameter Present study Kay et 
al.(99) 
Dhar et 
al.(67) 
Sehgal et 
al.(68) 
Country & year India (2016-
2018) 
England 
(1989-
1990) 
India 
(1987-
1994) 
India 
(2010-
2011) 
Number of patients 
with AD 
103 218 672 100 
Type of study P P P P 
Duration of study 1 yr 7 months 12 months 7yrs 6 
months 
1 yr 8 
months 
Mean age of onset Infants- 1.98 
months 
Children-1.98 
yrs 
Median- 6 
months 
Infants-4.2 
months 
Children- 
4.1 yrs 
3.63 + 1.42 
yrs 
Personal history of 
atopy 
46.6% 
(Asthma-
64.6% 
Allergic 
rhinitis-62.5% 
Allergic 
conjuncitivitis- 
20.8%) 
Asthma- 
38% 
10.86%  
(Infants- 
0.09% 
Children- 
15.37%) 
Asthma-
37% 
Allergic 
rhinitis- 
42% 
Family history of 
atopy 
66.02% - 36.9% - 
P- prospective 
 
Symptoms of AD occurred within the first year of life in 57.3% cases and within 5 
years of age in 89.3% cases. This was similar to the study done by Kay et al. wherein 
approximately 60% of cases occurred within the first year of life and 90% within 5 
years of age.(18) However, the age of onset of disease was lower in our study when 
compared to other Indian studies.(67,68) 
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Among precipitating and exacerbating factors in our study, sweating was the most 
common followed by food allergens, woollen clothing and dust-mites. Habitual 
scratching was reported by 6.8%. Werfel et al. compiled data from 8 studies and 
found a prevalence of food allergy varying between 33 to 63%.(100) Moderate to 
marked deterioration was observed in mildly involved skin of one-third patients with 
AD with positive skin-prick tests to house dust-mites when challenged with D. 
pteronyssinus in an earlier study.(101) Sweating and stress were reported as 
provoking factors in 96% and 81% patients, respectively in a study on 85 adult 
patients with AD.(102) 
 
In our study, seasonal variation was observed in 68% cases with 61.4% reporting a 
winter exacerbation, which was comparable to other studies from India and the West. 
Dhar and Kanwar reported it in  67.14% amongst the infantile AD and 58% amongst 
childhood AD,(67) while Sehgal et al. found the same in 70% patients (68). A study 
conducted in Germany on 39 children with eczema showed that 21 (53.8%) of them 
had aggravation in the winter season while 18 (46.2%) in the summer season.(103)  
 
At induction into the study, eczema on the face was observed in 86.7% cases in 
infantile AD but only 38.6% in childhood AD. This was similar to the study by Dhar 
et al. in case of infants where face was involved in 79%. However, it was much lower 
for childhood AD when compared to 74.5% children in the same study by Dhar et 
al.(67) It was higher than that found in the study by Sehgal et al. where 25% had 
facial involvement and 45% had involvement of the flexures(68). Chu et al. also 
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found highest involvement of head and neck region in infantile AD (25.3%).(104) In 
our study, both in infantile and childhood AD, acute eczema (93.3% and 63.6%, 
respectively) was the most common morphological type but chronic lesions were seen 
in a much higher number of children (57, 64.8%%) when compared to infants 
(26.7%). Dhar et al.(67) had also found a high number of infants with acute eczema 
(52.7% ), while in children predominant lesions were chronic involving 47.4% cases. 
This is in confirmation with the widely accepted opinion of acute lesions being more 
common in infants and chronic in children.(1,63,105) Erythroderma was seen in 6 
(5.8%) cases. Previous Indian studies have reported a prevalence of erythroderma of 
about 15% in children with AD.(106,107) 
 
Growth retardation, as assessed by height and weight below the 3rd centile was 
observed in 11.65% and 12.62% cases, respectively. Of these only 2 (15.4%) children 
with weight below 3rd centile and 4 (33.3%) with a height below 3rd centile had history 
of use of systemic steroids. This was similar to the study by Kristmundsdottir et al. 
wherein 10% children had a height lower than 3rd centile.(108) However, the growth 
retardation in cases recruited in our study was lower than the study by Dhar et al. 
where height and weight were below the 3rd centile in 34% and 42% children, 
respectively.(109) An association of central obesity with children suffering from AD 
has previously been described, wherein 15% children with AD had obesity.(110) In 
our study, there were 10 (9.7%) cases with weight above the 97th centile; 7 (70%) of 
them had obesity and 4 (40%) also had acanthosis nigricans. 
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Most common cutaneous bacterial infection reported in AD is Staphylococcus  
aureus, (80,111) which was the most frequent organism isolated in our study as well. 
Other studies have reported eczema herpeticum in the paediatric age group,(111) 
which was not seen in our study. 
 
Traditionally, severity assessment of AD is done by clinical scores such as SCORAD 
index, EASI and POEM. Recently, various biomarkers have been studied to help in 
assessing the severity of the disease. TARC is an important Th2 chemokine involved 
in homing CCR4 expressing T-cells to the skin and its production is upregulated by 
IL-1β and TNF-α.(85) Its levels have been found to correlate with disease severity 
elsewhere and we found a similar correlation with SCORAD in children above 2 
years of age. (Table 23)  
Table 23. Correlation coefficients (r) of severity scores versus laboratory 
parameters. 
 Present study  Kataoka 
(89) 
Kou et 
al.(10) 
Thijs et al.(11)* 
Age of 
patients 
>2yrs Adult 18-75yrs   
Type of 
study 
Case-control Cross-
sectional 
Cross-
sectional 
Longitudinal Cross-
sectional 
 r  p 
value 
r CI# r p value r  CI# r CI# 
Severity 
score 
SCORAD 
index 
EASI SCORAD 
index 
SCORAD in 59.4% studies 
TARC 0.538 <0.001 0.673 0.55-
0.77 
0.794 <0.001 0.60 0.48-
0.70 
0.64 0.57-
0.70 
Peripheral 
eosinophils 
0.397 <0.001 0.226 - 0.459 <0.001 - - - - 
LDH 0.582 <0.001 0.449 0.27-
0.60 
0.454 <0.001 - - 0.51 0.38-
0.62 
IgE 0.331 0.004 0.326 0.14-
0.50 
0.305 <0.01 0.33 0.08-
0.64 
0.45 0.32-
0.57 
*Meta-analysis 
#CI= Confidence interval (95%) 
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We found the highest correlation of SCORAD index with LDH (r=0.582) followed 
by serum TARC levels (r=0.538). Peripheral eosinophils and serum IgE also 
positively correlated with SCORAD index, though the relationship was lesser than 
with TARC (r=0.397 and 0.331, respectively). This was different from Japanese 
studies wherein TARC had the highest correlation with the severity score. However, 
LDH is non-specific and is released from tissues during damage, explaining the rise 
in its levels in many conditions like AD, malignancies, hemolysis etc.(11) Therefore, 
TARC levels being more specific for AD, is a more reliable biomarker.(11)  
 
Sensitivity and specificity of serum TARC measured by ELISA elsewhere ranged 
from 83-85% and 92-96%, respectively.(90) Normal serum TARC levels reported by 
Kataoka was 743 pg/mL for children above 2 years.(89) In our study, using the ROC 
curve as a tool for evaluation of TARC level as a diagnostic tool for AD, we found 
the cut-off to be 365pg/mL, which is lower than that reported by Kataoka.(89) The 
sensitivity and specificity in our study was found to be 57.7% and 72.3%, 
respectively.  The positive and negative predictive values were 77.6% and 50.8%, 
respectively for our sample, though these will differ based on the prevalence of 
disease in a population.  
 
The median TARC value was 519pg/mL (range 14 to 2503pg/mL) in cases and 
319pg/mL (range 46 to 2500pg/mL) in controls, the difference being statistically 
significant (p-value 0.004). This was in conformation with the finding of Hijnen et 
al., who had shown  statistically significant difference (p value of <0.001) between 
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patients with AD versus those without any allergic disease or with only a respiratory 
allergy (bronchial asthma, allergic rhinitis or both).(87) Therefore, it can be used as 
an adjunct to the clinical diagnosis of AD to differentiate diseased from the non-
diseased population. 
 
The role of vitamin D has also been implicated in the severity and pathogenesis of 
AD. Peroni et al. found higher vitamin D levels in mild AD compared to severe 
AD.(112) However, Chiu et al. did not find any significant correlation (r= -0.001, 
p=0.99).(113) Our study showed an inverse relationship between the levels of vitamin 
D and severity assessed by SCORAD index (r= -0.13) which was statistically not 
significant (p value 0.29). 
 
Severity of AD also correlated positively with QOL indices for children above 2 years 
in our study. A comparison with other studies is shown in table 24. This implies that 
children with a severe disease require psychosocial support since their quality of life 
is significantly impaired.  
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Table 24. Severity of AD versus QOL indices 
 Present study 
(Above 2 yrs) 
Cheng et al(77) Djurović et al(76) 
Severity 
score 
SCORAD index SCORAD index Three-item severity 
score 
 r  p 
value 
r p 
value 
Spearman's correlation 
coefficient (ρ)  
IDQOL 0.926 <0.001 0.358 <0.05 0.31-0.74 
CLDQI 0.541 <0.001 0.386 <0.05 0.31-0.69 
 
 
 
In children above 2 years of age, a significant correlation was found between serum 
TARC levels and objective SCORAD, SCORAD index, IDQOL and CDLQI scores.  
It also correlated with other objective markers of severity such as peripheral 
eosinophils and LDH. We did not find a similar correlation for children under 2 years. 
However, the number studied was small (n=25). A comparison of correlation of 
TARC levels with other clinical and laboratory parameters in children older than 2 
years with another study in Japan is given in table 25. 
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Table 25. Correlation coefficient between serum TARC levels and other 
clinical and laboratory parameters 
Parameter Present study 
(for age> 2yrs) 
Kakinuma et al.(85) 
 r p value r p value 
1. Objective 
SCORAD 
0.52 
 
<0.001 0.60 
 
<0.001 
2. SCORAD 
index 
0.54 <0.001 - - 
3. Peripheral 
eosinophils 
0.58 
 
<0.001 0.61 <0.001 
4. LDH 0.55 <0.001 - - 
5. IgE 0.17 0.19 0.57 <0.001 
The significant values are highlighted in bold 
 
TARC levels correlated with SCORAD, peripheral eosinophils and LDH similar to 
the study by Kakinuma et al.  
 
In summary, the clinical profile of our patients was similar to other studies, in terms 
of age of onset, precipitating and exacerbating factors, morphology of lesions and 
secondary bacterial infections. The complications of growth retardation, obesity and 
secondary viral infections were lower in our study. There was a significant difference 
in levels of TARC in AD and controls, suggesting the usefulness of TARC to aid in 
the diagnosis of AD. We also found a positive correlation of serum TARC levels with 
SCORAD index, quality of life indices and other biomarkers in children above 2 years 
of age, which indicates that TARC levels may be used as an objective marker of 
disease severity. This is in confirmation to most other studies conducted 
elsewhere.(11)
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CONCLUSION 
 
• In this hospital-based case-control study, the mean age of children with AD was 
5.78 years in males and 6.55 years in females. The majority of children were 
older than 2 years and the ratio of male: female was 1.7:1, which was similar to 
other Indian studies.(67,68) 
• AD manifested by 1 year of age in 57.3% and by 5 years in 89.3% of children. 
• Sweating was the most common exacerbating factor followed by food allergens, 
woollen clothing and dust-mites. 
• Face was the most common site affected (83,80.6%) irrespective of the age 
group. 
• Acute eczema was the most common morphological type present in 70 out of 
103 patients (68%) with or without lichenification (56,54.3%). Erythroderma 
was seen in 6 (5.8%) cases. The prevalence of acute eczema was significantly 
higher in the infantile group (<18 months) as compared to childhood group (>18 
months) (p value of <0.001). On the other hand, chronic AD comprising of 
lichenification, prurigo and psoriasiform lesions was more common in the 
childhood group (p value of 0.042). 
• Growth retardation was not significant in our sample as majority of the cases 
were between 3rd to 97th centile of height (78.64%) and weight (77.67%). 
Obesity was seen in 8.9% children. 
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• TARC levels were elevated in 33 (32%) cases. The median TARC value was 
519pg/mL (range 14-2503pg/mL) in cases and 319pg/mL (range 46-
2500pg/mL) in controls (p-value 0.004).  
• The cut-off obtained for TARC level in AD by the ROC curve analysis was 
365pg/mL (for children above 2years), with a sensitivity of 57.7%, specificity 
of 72.3%, positive predictive value of 77.6% and negative predictive value of 
50.8%.  
• The mean SCORAD index was 37.21+ 22.0. This correlated with TARC levels 
in children above 2 years (r= 0.52, p-value <0.001) and with other biomarkers 
like LDH (r=0.55), serum IgE (r=0.31) and peripheral eosinophils (r=0.37). 
• TARC levels correlated significantly with QOL indices in children above 2 
years (IDQOL: r=0.823, p-value=0.003 and CLDQI: r=0.380, p-value=0.001). 
• Our study has shown that serum TARC can be used as an adjunct to the clinical 
criteria for the diagnosis of AD and correlates with disease severity as   assessed 
by SCORAD.
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LIMITATIONS  
• The study is from a single centre and hence the sample may not be 
representative of a large population. 
• The number of children below 1 year and between 1-2 years were very 
limited and hence we could not determine a definite relationship between the 
clinical and laboratory parameters or plot the ROC curve in these groups. 
• Patients were examined only once during the study period, therefore we 
could not study the effect of treatment on the level of biomarkers and its 
effectiveness as a prognostic marker. 
 
RECOMMENDATIONS 
• Multicentre studies are needed to study the efficacy of serum TARC as a 
diagnostic marker and to assess its relationship with the disease severity. 
• Prospective studies are required to study its efficacy as a prognostic marker to 
prevent undue early termination of treatment. 
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SUMMARY 
 
Background: 
Atopic dermatitis (AD) is a pruritic, chronic inflammatory skin disease which is 
diagnosed by clinical criteria such as the Hanifin and Rajka criteria, the U.K. Working 
Party Diagnostic criteria etc. Its severity is determined using clinical scoring systems, 
such as SCORing Atopic Dermatitis (SCORAD), Eczema Area and Severity Index 
(EASI) and Patient Oriented Eczema Measure (POEM). There are several biomarkers 
also to assess the severity such as serum thymus and activation-regulated chemokine 
(TARC), IL-18, lactate dehydrogenase (LDH), IgE and peripheral blood eosinophils, 
of which TARC has shown promising results elsewhere. There are no published 
studies in India assessing the correlation between serum TARC levels and AD and its 
severity. This study was undertaken to evaluate the same in the Indian subcontinent. 
 
Objectives: 
Our primary objective was to study the efficacy of TARC as a diagnostic marker of 
AD and its association with the severity of the disease in the paediatric age group in 
the Indian context and to study the clinical profile of patients with AD. Secondary 
objective was to study the quality of life of patients with AD and its correlation with 
serum TARC.  
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Methods: 
A hospital-based case-control study was conducted in the department of 
Dermatology, Venereology and Leprosy, Christian Medical College, Vellore over a 
period of 19 months from December 2016 to June 2018, with approval from the 
Institutional Review Board (IRB. No. 10320). 103 patients aged 0-16 years with AD 
and 70 controls with diseases mimicking AD (psoriasis, scabies, contact dermatitis, 
seborrheic dermatitis, impetigo) were recruited after an informed written consent. 
Data was entered into a standard clinical proforma. The UK Working Party 
Diagnostic Criteria was used to diagnose AD. TARC levels were measured using 
Abcam’s Human ELISA kit. Other laboratory parameters tested included LDH, 
serum IgE and peripheral eosinophils. Severity of AD was assessed by calculating 
SCORAD index. Quality of life was assessed using IDQOL for children below 4 
years and CDLQI for those above 4 years. Receiver-operating-characteristic curve 
was plotted for optimal cut-off value for TARC and correlation was determined using 
Pearson-correlation-coefficient and linear regression. 
 
Results: 
103 (65-males,38-females) cases and 70 (38-males,32-females) controls were 
recruited with mean age (years) of 6.06 and 6.52, respectively. AD manifested by 1 
year of age in 57.3% and by 5 years in 89.3% of children, the face being the most 
common site affected (83,80.6%). In infantile AD (n=15), 14 (93.3%) cases had acute 
eczema and 4 (26.7%) had lichenification in addition. In childhood AD (n=88), 56 
(63.6%) cases had acute eczema, 52 (59.1%) had lichenification, 2 (2.3%) had prurigo 
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and 3 (3.4%) had psoriasiform lesions. Erythroderma was seen in 6 (5.8%) cases. All 
features of filaggrin mutation were seen in 10 (9.7%) cases. Xerosis was seen in 88 
(85.4%) patients. Dennie-Morgan folds were seen in 20 (19.4%) cases. The median 
TARC value was 519pg/mL (range 14-2503pg/mL) in cases and 319pg/mL (range 
46-2500pg/mL) in controls (p-value 0.004).  A cut-off of 365pg/mL was obtained in 
AD (children>2years) using the ROC curve (sensitivity-57.7%, specificity-72.3%, 
positive-predictive-value-77.6%, negative-predictive-value-50.8%). The mean 
SCORAD index was 37.21+ 22.0. This correlated with TARC levels in children 
>2years (r= 0.52, p-value <0.001) and also with other biomarkers like LDH (r=0.55), 
serum IgE (r=0.31) and peripheral eosinophils (r=0.37). TARC levels correlated 
significantly with QOL indices in children >2 years (IDQOL-r=0.823, p-value=0.003 
and CLDQI-r=0.380, p-value=0.001).  
 
Conclusion: 
The clinical profile of our patients was similar to previous studies. Our results suggest 
that serum TARC is a useful adjunct to the clinical criteria for the diagnosis of AD 
and correlates with the severity of disease as well and can, therefore, provide an 
objective assessment of severity in AD. 
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ANNEXURES 
ANNEXURE-1 : CONSENT FORMS, CHILD ASSENT FORMS & 
PATIENT INFORMATION SHEETS               
Informed Consent form to participate in a clinical trial 
Study Title: To study the efficacy of thymus and activation-regulated chemokine 
(TARC) as a diagnostic marker of atopic dermatitis and its association with the 
severity of the disease in the paediatric age group in the Indian context 
 
Study Number: 
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________ 
Date of Birth / Age: ___________________________ 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask questions.   
[  ] 
(ii)  I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected. [  ] 
(iii)  I understand that the Sponsor of the clinical trial, others working on the 
Sponsor’s behalf, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published. [  ] 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
(v)  I agree to take part in the above study. [  ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
Or 
 
 
Representative: _________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
Signature (or) thumb impression of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name and Address of the Witness: ______________________________ 
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शोध अध्ययन में भाग लेन ेके ललए सूचित सहमत पत्र 
अध्ययन शीर्षक: एटॉपिक डरे्मटाइटटस से िीड़ित बच्चों (०-१६ वर्ष) के थाइर्मस एंड 
एक्टटवेशन-रेगुलेटेड कीर्मोकाइन (TARC) का सीरर्म स्तर और बीर्मारी की गहनता से 
उसका सम्बन्ध  
अध्ययन संख्या:  
प्रततभागी का नार्म: ___________________ 
जन्र्मततथथ / उम्र : ______________ 
१) र्मैं इस बात की िुक्टट करता ह ं कक र्मैंने टिनांक ______________ स चना ित्र को उिरोटत 
अध्ययन के ललए िढ़ा और सर्मझा है, और र्मुझे प्रश्न ि छने का र्मौका लर्मला है। 
२) र्मैं इस बात को सर्मझता ह ं कक इस अध्ययन र्में रे्मरी भागीिारी स्वैक्च्छक है। र्मैं ककसी भी 
सर्मय बगैर कोई कारण बताए, तथा रे्मरी थचककत्सा र्में बबना कोई बाधा आए, या कान नी 
अथधकार बबना प्रभापवत हुए, इस अध्ययन को छोि सकता ह ं। 
३) र्मैं सर्मझता ह ं कक आचार सलर्मतत और तनयार्मक अथधकाररयों को रे्मरे स्वास््य अलभलेखों 
के वतषर्मान अध्ययन और इस संबंध र्में भपवटय र्में होने वाले अनुसंधानों के ललए रे्मरी 
अनुर्मतत की जरूरत नही होगी, चाहे र्मैं इस से अिनी भागीिारी वािस ले ल । र्मैं इस बात से 
सहर्मत ह ं। 
हालााँकक, र्मैं सर्मझता ह ं रे्मरी िहचान का खुलासा तीसरे िक्ष को िी गई ककसी भी जानकारी 
अथवा  प्रकाशन र्में नहीं ककया जाएगा 
४) र्मैं इस बात के ललए सहर्मतत िेता ह ं कक इस अध्ययन से उत्िन्न हुए िररणार्मों को 
वैज्ञातनक प्रायोजन के ललए प्रिान करन ेसे इंकार नहीं करूगा। 
५) र्मैं उिरोटत अध्ययन र्में भाग लेन ेके ललए सहर्मत ह ं। 
हस्ताक्षर या अगं ठे का तनशान (पवर्य / कान नी तौर िर स्वीकायष प्रतततनथध): 
हस्ताक्षरकताष का नार्म: ____________________________  टिनांक: ____ / ____ / 
_____ 
अन्वेर्क के हस्ताक्षर: ________________________ 
टिनांक: _____/_____/______ 
अध्ययन जांचकताष का नार्म: _________________________ 
गवाह के हस्ताक्षर या अंग ठे का तनशान: ___________________________ 
टिनांक: _____/_____/_______ 
गवाह का नार्म व िता: _____________________________________________ 
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மருத்துவ ஆராய்ச்சியில் பங்கெற்ப்ப்தற்ொன  ஒப்புதல் படிவம் 
 
ஆய்வின் தலைப்பு:  லதமஸ் மற்றும் டி ஏ ஆர் ஸி யின் இரத்த அளவு 
ஏட்டொப்பிக் கெர்மலெடிஸ் உள்ள குழந்லதெளில் ஆராய்ந்து அதற்க்கும் 
ட ாயின் தீவிரத்திற்கும் உள்ள உறலவயும் குறித்து ஆராய்தல். 
 
எண்: 
பங்கெற்பவரின் லெகயாப்பம்: 
பங்கெற்பவரின் கபயர்: 
பிறந்த டததி/ வயது: 
 
(i) இந்த ஆராய்ச்சியில்  ான் தெவல் படிவதிலுள்ள எல்ைா விவரஙெலளயும் 
படித்து அறிந்துக்கொண்டென். டெள்விெள் டெட்ெ வாய்ப்பளிக்ெப்பட்ெது. 
 
(ii) இந்த ஆரய்ச்சியில் பங்குடொள்வது என் விருப்பம்சார்ந்தது என்றும், 
இவ்வாராய்ச்சியில் இருந்து எப்டபாது டவண்டுமானாலும், எக்ொரணமுமின்றி 
விைெிக்கொள்ளைாம் என்றும் புரிந்து கொண்டென். என்னுலெய விைெல் என் 
மருத்துவ சிெிச்லசக்ொன எந்த ஒரு உரிலமலயயும் பாதிக்ொது என்பலதயும் 
புறிந்துகொண்டென். 
 
(iii) இந்த ஆராய்ச்சி சம்பாந்தமான கபாறுப்பில் உள்ளவர்ெள் சட்ெப்பூர்வமான 
குளுலவச்சார்ந்தவர்ெள் மற்றும் ஒழுங்குமுலறக் குழுலவச் சார்ந்தவர்ெள் 
என்றும் என்னுலெய மருத்துவ பதிடவடுெலள என் அனுமதியில்ைாமல் 
பயன்படுத்தைாம் என்பதற்க்கு முழு சம்மதம் கதறிவிக்ெிடறன். இந்த 
ஆய்விைிருந்து  ான் விைெினாலும் அவர்ெள் என் பதிடவடுெலள பயன் 
படுத்தைாம் என்றும் ஆய்வு முடிவுெள் கவளியிெப்படும் கபாது என் கபயரும் 
எண்லணக் குறித்த தெவல்ெளும் கவளியிெப்பொது என்பலத  ன்கு அறிடவன். 
 
(iv) இந்த ஆராய்ச்சியில் கபறப்படும் தெவல்ெலள அறிவியல் சம்மந்தமாெ 
பயன்படுத்துவதில் எனக்கு எந்த மறுப்பும் இல்லை. 
 
இரெசியத்தன்லம: 
 
இந்த ஆய்வில் உங்ெள் கபயடரா அல்ைது முெவரிடயா எந்த இெத்திலும் 
குறிப்பிெ பொது. இந்த ஆய்வின் கபாழுது உங்ெலளப் பற்றி கபறப்பட்ெ 
அலனத்து தெவலும் மிெவும் பாதுொப்பாெவும், இரெசியமாெவும் லவக்ெப்படும். 
டமலும் இத்தெவலை டதலவப்படும் கபாது சட்ெவிதிமுலறக்குட்பட்டெ 
பயன்படுத்தப்படும். 
 
பங்குகபறுவது: 
 
இந்த ஆய்வில்  ீங்ெல் பங்குகபறுவது அல்ை பங்குகபற மறுப்பது உங்ெள் 
விருப்படம. இந்த ஆய்வின் கபாழுது எந்த ட ரத்திலும் அந்த ொரணத்தினாலும் 
தானெடவ விைெிக்கொள்ளைாம். டமலும்  ீங்ெள் விைெினாடைா அல்ை 
பங்குகபற மறுத்தாடைா அதனால் தாங்ெள் கபறும் மருத்துவ சிெிச்லசயில் எந்த 
வித பாதிப்பும் ஏற்பொது. 
 
அணுெவும்: 
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ொக்ெர். ஹிமாத்ரி ஸின்ஹா 
பாைியல் மற்றும் கதாழு ட ாய் பிரிவு - 1 
ெிறிஸ்த்துவ மருத்துவக் ெல்லூரி 
டவலூர்  
 
லெகயழுத்து: 
லெகயழுத்திட்ெவரின் கபயர்: 
டததி: 
 
ஆய்வாளரின் லெகயழுத்து: 
ஆய்வாளரின் கபயர்: 
டததி: 
 
சாட்சியாளரின் லெகயழுத்து: 
சாட்சியாளரின் கபயர் மற்றும் முெவரி: 
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কককনককল টকযকল গববষণকয অঅশগহবণর কলকখত অননমকত পত 
সককড কশবরকনকম : 
এটটটপপক ডটররটটটইপটস চররটরটটগ আকটন ০-১৬ বছর বয়সস পশশটদর রটক ' থটইরটস ও এপকটভশন পনয়পনত ককটরটকটইন 
(TARC) ' নটরক পদটটথরর রটতট সরসকট কটর এই করটটগর তসবতটর সটঙ তটর সমকর পনররয় 
গববষণক অননকমকঙ : 
অঅশগহরকটরসর নটটরর আদদকর : ______________ 
অঅশগহরকটরসর নটর: __________________ 
জনপতপথ / বয়স ________ হটসপটতটল নন ______________________ 
পটক পচপহত করন : 
i . এই গটবষনটর তথদপত আপর পটড়পছ এবঅ সমমররভটটব ববটঝপছ, এবঅ তট সঅকটন পশ করটর আরটটক সরয় ও 
সবটযটগ কদয়ট হয়টছ । ( ) 
ii . এই গটবষরটয় আপর কসছটয় অঅশগহন করপছ । কয ককটটনট রবহটতর আপর চটইটল এর কথটক অনবরপত পতদটহটর 
কটর 
পনটত পটপর এবঅ তটর ককটনরকর পভটব এই হটসপটতটটল আরটর বতর রটন বট আগটরস পচপকৎসটয় বট আইপন 
অপধকটটরর 
উপর পড়টব নট । ( ) 
iii . এই অঅশগহটন সমপত থটকটর ফটল আরটর সমটন সঅগহ করট তথদটপদ বদবহটর করটত গটবষনটকতর টর আর 
ককটটনট 
অনবরপত লটগটব নট, পকন আরটর পপরচয় ককটটনট তত তসয় কতর টটক জটনটটনট হটব নট, এবঅ ককটথটও পকটশ 
করট হটব নট । 
( ) 
iv . এই গটবষনটর ককটটনট তথদটপদ ও ফলটফল বদবহটটর আপর ককটনরকর বটধট কদব নট, যপদ তট ববজটপনক 
কটটজর 
ককটত বদবহত হয় । ( ) 
v . এই গটবষরটয় অঅশগহন করটত আপর সমত । ( ) 
______________________________________ 
সটকর / পটপ সই ( অঅশগহনকটরসর / আইনত গহরটযটগদ পপতপনপধ র ) 
সটকরকটরসর নটর : _______________________ তটপরখ : ____/_____/_____ 
______________________________________ 
তদনকটরসর সটকর 
তদনকটরসর নটর : __________________________ 
তটপরখ : ____/_____/_____ 
______________________________________ 
সটকসর সটকর / পটপ সই 
তটপরখ : ____/_____/_____ 
সটকসর নটর ও পঠকটনট : ____________________________________________ 
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CHILD ASSENT FORMS 
Title of the study: To study the efficacy of thymus and activation-regulated 
chemokine (TARC) as a diagnostic marker of atopic dermatitis and its 
association with the severity of the disease in the paediatric age group in the 
Indian context 
 
Protocol number: 
Principal investigator: Dr. Himadri 
 
Address: Department of Dermatology, Venereology and Leprosy Unit 1, Christian 
Medical College (CMC), Vellore. Phone no: 0416-2283527 
 
Location where the study will be conducted: Department of Dermatology, 
Venereology and Leprosy Unit I, Christian Medical College, Vellore 
 
We want to tell you about a study we are doing. A research study is a special way to 
find out more about a disease. We are trying to find out the relationship between 
serum levels of TARC and a disease called atopic dermatitis. You are being asked 
to join the study because we feel that you are a ideal subject for the causes being 
studied. 
The doctor will examine your skin thoroughly and take down the details in a 
special proforma. If felt necessary she would click photographs of the skin lesions. 
For some tests, blood would need to be withdrawn. We would see you only once in 
the study period. Follow ups are welcome though not absolutely necessary for this 
study. 
 
Can anything bad happen to me? 
We want to tell you about some things that might hurt or upset you if you are in this 
study.   
The most common side effects from blood drawing include: 
- Pain 
- Bleeding at the puncture site 
- Slight possibility of infection or fainting 
 
Can anything good happen to me? 
 We don’t know if being in this research study will help you feel better or get well. 
But we will be able to tell you something which can be used for monitoring the 
treatment of your disease. 
 
Will anyone know I am in the study? 
We will not tell anyone that you took part in this study. When the study is 
completed, we 
will write a report about what we find out. We won’t use your name in the report. 
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What happens if I get hurt? 
There is a negligible risk of getting hurt and your parents/ guardians have been 
informed 
about the same. 
 
What if I do not want to do this? 
You don’t have to be in this study. It is entirely your wish. If you agree now, but 
refuse 
later, that is okay too. All you need to do is to tell us. 
If you want to participate in this study, please sign below – 
[ ] Yes, I want to be a part of this study 
[ ] No, I do not want to be a part of this study 
Name of the child: 
Signature/ thumb impression of the child: 
Date: 
 
Witness mediator 
Name: 
Signature/thumb impression: 
Date: 
 
Person obtaining Assent: 
I have explained the research at a level that is understandable by the child and 
believe 
that the child understands what is expected during the study. 
Name of the investigator: Dr Himadri 
Signature: 
Date: 
Witness mediator 
Name: 
Signature: 
Date: 
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बाल सहमतत पत्र 
शोध का शीर्षक: एटॉपिक डर्मेटाइटटस से िीड़ित बच्चों (०-१६ वर्ष) के थाइर्मस एंड एक्टटवेशन-
रेगुलेटेड कीर्मोकाइन (TARC) का सीरर्म स्तर और बीर्मारी की गहनता स ेउसका सम्बन्ध  
प्रोटोकॉल संख्या: 
प्रधान अन्वेर्क: डॉ. टहर्माटि 
अध्ययन का स्थान: डर्मेटोलॉजी, वेनेरेओलोक्ज और कुटठ रोग पवभाग, किक्स्टयन र्मेड़डकल कॉलेज, 
वेल्लोर। ि रभार्: ०४१६-२२८३५२७ 
 
हर्म आिको इस अध्ययन के बारे र्में बताना चाहते हैं। एक रोग के बारे र्में अथधक जानकारी प्राप्त 
करने के ललए शोध ककया जाता है।  हर्म एटॉपिक डर्मेटाइटटस नार्मक बीर्मारी और TARC के सीरर्म 
स्तर के बीच का सम्बन्ध ढ ंढने का प्रयास कर रहे हैं। आिसे अनुरोध ककया जाता है कक आि इस 
शोध का टहस्सा बनें टयोंकक हर्मारा र्मानना है कक आि इस अध्ययन के ललए उियुटत कताष हैं।  
डॉटटर आिकी त्वचा की ि णष रूि से जांच करने के िश्चात ्एक पवशरे् प्रोफॉर्माष र्में पववरण ललखेंगीं। 
आवश्यकता ििने िर आिकी त्वचा की तस्वीर ली जा सकती है। कुछ जांच के ललए आिके ख न का 
नर्म ना ललया जायेगा। हर्म आिको अध्ययन के िौरान केवल एक बार िेखेंगे। िुनतनषरीक्षण अतनवायष 
नही ंहै ककन्तु अिेक्षक्षत है।  
 
क्या इस अध्ययन में भाग लेने से मुझ ेकुछ नुकसान पहुुँि सकता है? 
हर्म आिको कुछ बात बताना चाहते हैं क्जसस ेआि पवचललत हो सकते हैं। ख न तनकालने की 
संभापवत जटटलताएं तनम्नांककत हैं: 
- ििष 
- िंटचर के स्थान रटत स्त्राव  
- इन्फेटशन या बेहोश होने की सम्भावना 
 
इस अध्ययन में भाग लेने से मुझ ेक्या फायदा होगा? 
हर्म नहीं जानते कक इस अध्ययन र्में भाग लेने से आिके स्वास््य र्में कोई सुधर आएगा या नहीं। 
िरंत ुहर्म आिको कुछ जानकारी िे िाएंगे क्जसस ेआिकी बीर्मारी के इलाज की तनगरानी संभव 
होगी।  
  
क्या ककसी और को पता िलेगा कक मैं इस अध्ययन का हहस्सा हूुँ? 
हर्म ककसी को नहीं बताएाँगे कक आिने इस अध्ययन र्में भाग ललया।  अध्ययन सर्माप्त होने िर हर्म 
एक ररिोटष तैयार करेंगे क्जसर्में हर्म आिका नार्म नहीं ललखेंगे।  
 
यहद मुझ ेिोट लगी तो क्या होगा? 
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आिको चोट लगने की सम्भावना नगण्य है। ककन्तु आिके र्माता-पिता को स थचत कर टिया गया है 
कक यटि आिको ककसी प्रकार की िरेशानी हो तो वे तुरंत आिको डॉटटर के िास टिखाएं।  
 
यहद मैं इस अध्ययन में भाग न लेना िाहूुँ तो मुझ ेक्या करना पड़गेा? 
अध्ययन र्में भाग लेने का तनणषय आिका है। यटि आि इसर्में शालर्मल होने स ेसहर्मत होकर कफर 
शालर्मल न होना चाहें तब भी कोई र्मुक्श्कल नहीं है।  आिको केवल अिना तनणषय हर्में बताना है। 
यटि आि इस अध्ययन र्में  भाग लेना चाहते हैं तो कृिया नीच ेहस्ताक्षर करें।  
[  ] हाुँ, मैं इस अध्ययन में भाग लेना िाहता/िाहती हूुँ 
[  ] नह ीं, मैं इस अध्ययन में भाग नह ीं लेना िाहता/िाहती हूुँ 
बच्च ेका नार्म: 
हस्ताक्षर/ अगं ठे का तनशान: 
टिनांक: 
 
गवाह मध्यस्थ 
नार्म: 
हस्ताक्षर/ अगं ठे का तनशान: 
टिनांक: 
 
स्वीकृतत प्राप्त करने वाला व्यक्क्त 
र्मैंने इस अध्ययन के बारे र्में बच्च ेको उसके द्वारा सर्मझने वाले स्तर िर सर्मझाया है।  र्मेरा 
पवश्वास है की बच्चा यह सर्मझ गया है कक अध्ययन र्में भाग लेने स ेउसे टया करना ििगेा।  
शोधकताष का नार्म: डॉ. टहर्माटि 
हस्ताक्षर: 
टिनांक: 
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ஒப்புதல் படிவம் 
 
ஆராய்ச்சியின் தலைப்பு : லதமுஸ் சுரப்பியும் அதன் கசயல்பாலெ 
 ிர்ணயிக்கும் ெீகமாக்லெனும் எட்கொப்பிக் கெர்மலெடிஸ் வியாதியில் 
கசயல்படும் விதம் 
 
படிவ எண்: 
 
ஆராய்சியாளர்: மருத்துவர் ஹிமாத்ரி ஸின்ஹா 
 
விைாசம்: டதால் ட ாய் பிரிவு, பாைியல் மற்றும் டதால் ட ாய் பிரிவு எண்: 1, 
                ெிறஸீ்துவ மருத்துவக் ெல்லூரி, கவல்லூர். 
                கதாெர்பு எண்: 0416 2283527 
 
ஆராய்ச்சி கசய்யப்படும் இெம்: பாைியல் மற்றும் டதால் ட ாய் பிரிவு எண்:1, 
                                                  ெிறிஸ்துவ மருத்துவக் ெல்லூரி, கவல்லூர். 
 
 ாங்ெள் தங்ெளுக்கு  ாங்ெள் கசய்யும் ஆராய்ச்சிலய பற்றி கூற 
விரும்புெின்டறாம். ஆராய்ச்சி என்பது ஒரு வியாதிலய குறித்து டமலும் அறிந்து 
கொள்வதர்க்ொன ஓர்  ல்ை வழியாகும்.  ாங்ெள் இப்டபாது ஏட்டொப்பிக் 
கெர்மலெடிஸ் என்ெின்ற வியாதிக்கும் டிஏஆர்ஸி என்ெின்ற திரவம் 
இரத்தத்தில் இருப்பதற்கும் உள்ள சம்பந்த்தத்லத அறிய விரும்புெின்டராம். 
தாங்ெள் எங்ெள் ஆராய்ச்சிக்கு உதவியாெ இருப்பரீ்ெள் என்று ெருதுெிடறாம்.  
 
இதற்க்ொெ, மருத்துவர் தங்ெள் சருமத்லத  ன்றாெ டசாதலன கசய்து 
ெண்டுபிடிப்புெலள ஒரு தனி தாளில் எழுதுவார்ெள். 
 
டதலவ பட்ொல் டதாைில் உள்ள புண்ெலள புலெப்பெம் பிடிப்பார்ெள். சிை 
ஆய்வுக்ொெ இரத்தம்  எடுக்ெப்படும். இந்த ஆரய்ச்சிக்ொைம் முழுதிலும்  ாங்ெள் 
உங்ெலள ஒரு முலற மட்டுடம சந்திக்ெ டதலவ உண்டு. ஆனாலும், தாங்ெள் 
விருப்பப்பட்ொல் எங்ெலள மீண்டும் வந்து சந்திக்ெ அனுமதி உள்ளது. 
 
எனக்கு ஏகதனும் சிரமம் உண்ொகுமா? 
 
இரத்தம் எடுத்தைால், சிறிது வைி, இரத்தக் ெசிவு, மயக்ெம், ஆெியலவ உண்ொெ 
வாய்ப்பு உள்ளது. 
 
எனக்கு  ல்ைது ஏகதனும்  ெக்குமா? 
 
இதன் மூைமாெ தினசரி வாழ்க்லெயில் பயன் இல்ைாவிட்ொலும், இதன் 
மூைமாெ ெிலெக்கும் கசய்திெலள பயன்படுத்தி  ாங்ெள் தங்ெள் ட ாலயக் 
குறித்து பை விஷயங்ெலள அறிந்து கொள்ள முடியும். 
 
இலத பற்றி யாருக்ொவது கதறிய வருமா? 
 
 ீங்ெள் இந்த ஆரய்ச்சியில் பங்குகபற்றது குறித்து  ாங்ெள் யாருக்கும் கசால்ை 
மாட்டொம். டமலும் இதில் டசெறித்த விவரங்ெலள கவளியடீு கசய்யும் டபாது 
தங்ெள் கபயலர இெ மாட்கொம். 
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எனக்கு அடி பெ வாய்ப்பு உள்ளதா? 
 
இருக்கும் சிறிய வாய்ப்பு தங்ெள் கபற்கறாரிெம் கசால்ை பட்டுள்ளது. 
 
எனக்கு பங்குகபற விருப்பம் இல்லைகயன்றால்? 
 
இது முழுக்ெ முழுக்ெ தங்ெள் விருப்பத்துக்கு உற்ப்பட்ெடத. தாங்ெள் எப்டபாது 
டவண்டுமானலும் பங்குகபற மறுக்கும் வசதி உள்ளது. 
 
இதில் பங்கு கபற விருப்பம் இருந்தால் ெீடழ லெகயாப்பமிெவும். 
 
ஆம், பங்குகபற விருப்பப்படுெிடறன்: [ ] 
 
இல்லை, பங்குகபற விருப்பமில்லை:[ ] 
 
குழந்லதயின் கபயர்: 
குழந்லதயின் லெகயாப்பம்: 
டததி: 
 
சாட்சியாளர்: 
கபயர்: 
லெகயாப்பம்: 
டததி: 
 
ஒப்புதல் வாங்குபவர்: 
 ான் குழந்லதக்கு அதற்க்கு புரியும் கமாழியில், புரியும் வண்ணத்தில் 
கூறியுள்டளன். குழந்லத, ஆராய்ச்சிலயக் குறித்த சரியான் தெவல்ெலள கபற்று 
இருக்ெிறது என்று  ம்புெிடறன். 
 
ஆராய்ச்சியாளர் கபயர்: 
லெகயாப்பம்: 
டததி: 
 
சாட்சியாளர்: 
கபயர்: 
லெகயாப்பம்: 
டததி 
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শশশর সমশত পত 
সসডড ডশররসনসম : 
এটটটশপক ডটররটটটইশটস চররটরটটগ আকটন ০-১৬ বছর বয়সস শশশটদর রটক ' থটইরটস 
ও এশকটভশন 
শনয়শনত ককটরটকটইন (TARC) ' নটরক পদটটথরর রটতট সরসকট কটর এই করটটগর 
তসবতটর সটঙ তটর সমকর 
শনররয় 
পপসরটসকল সসখখস : 
পধসন তদনকসরর : ডড ডহমসদর 
ডঠকসনস : চমরররসগ , পযযনররসগ ও কক ষ পরসগ ডবভসগ, ইউডনট 1 ( DVL 1 ) , ডখসসন 
পমডডরকল করলজ , পভরলসর 
পফসন নড 0416- 2283527 
গরবষণস পযখসরন হরব পসখসনকসর ডঠকসনস : চমরররসগ , পযযনররসগ ও কক ষ পরসগ ডবভসগ, 
ইউডনট 1 ( DVL 1 ) , ডখসসন 
পমডডরকল করলজ , পভরলসর 
পতসমসরক আমরস একডট গরবষণসর বখসপসরর বলরত চসই , পযডট আমরস এখসরন করডছ। গরবষণস 
মসরন হরচ একডট ডবরশষ উপসয় 
, পকসরনস পরসগ-এর বখসপসরর যসরত আমরস আররস পবডশ জসনরত পসডর। আমরস এরটসডপক 
ডসমরসটসইডটস পরসগ এর সসরথ TARC 
নসরমর ররক পসওয়স একডট পদসরথরর পযসগসরযসগ পবসঝসর পচষস করডছ এই গরবষণসয়। পতসমসরক আমরস এই 
গরবষণসয় পযসগ ডদরত 
বলডছ কসরণ আমসরদর ধসরণস পয পয পরসগডট ডনরয় আমরস কসজ কররবস, এটসর গরবষণসর জনখ তক 
ডম আদশর পসথরর । 
একজন ডসকসর পতসমসর সসরস শররররর তক ভসরলসভসরব পররকস করর পদরখ একডট ডবরশষ ফরমর 
তস ডলরখ পনরবন। যডদ তসর 
দরকসর মরন হয় তসহরল পস পতসমসর চসমড়সয় হওয়স ফক সকক ডড়, ঘস এগডলর ছডব ও তক লরত 
পসররন। ডকছক পটস কররত রক 
পররকস করসর দরকসর ও পড়রব। এই গরবষণসর জনখ পতসমসরক আমসরদর কসরছ খসডল একবসরডট 
আসরত হরব, তসর পর আসসর 
দরকসর পনই ডকন তক ডম চসইরল আবসর আসরত সসগত , যডদও এই গরবষণসর জনখ তসর পসভসরব 
পরয়সজন পনই। 
এই গটবষরটয় ভটগ শনটল আরটর শক শকছছ খটরটপ হটত পটটর ? 
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এই গরবষণসয় ভসগ ডনরল এমন ডকছক যসর কসররণ পতসমসর বখসথস বস কষ হরত পসরর , তসর 
বখসপসরর পতসমসরক আমরস জসনসরত 
চসই। 
সবরচরয় সসধসরণভসরব রক পররকস করসর ফরল এগডল হরত পসরর - 
- বখসথস 
- রক পররকসর জসয়গসয় রক পবররসরনস 
- সসকমণ হওয়সর বস অজসন হরয় যসওয়সর হসলকস সমসবনস 
এই গটবষরটয় ভটগ শনটল আরটর শক শকছছ লটভ হটত পটটর ? 
এই গরবষণসর কসররণ পতসমসর পরসগ ভসরলস হওয়সর পকরত পকসরনস লসভ হরব ডকনস তস আমরস 
এখরনস জসডননস ডকন এর পথরক 
পসওয়স ফলসফল ডদরয় আমরস পতসমসর পরসগডটর ডচডকৎসসর পযররবকণ কররত পসররবস। 
অনন ককউ শক জটনটত পটরটব কয আশর এই গটবষরটয় ভটগ শনটয়শছ ? 
নস, এইটস আমরস কসউরক জসনরত পদব নস পয তক ডম এরত ভসগ ডনরয়রছস। গরবষণসর পশরষ 
ফলসফল ডনরয় আমরস একটস ডররপসটর 
ডলখরবস। এই ডররপসটর এ পতসমসর নসম পকসশ করস হরবনস। 
আরটর ককটটনট কশত হটল শক হটব? 
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PATIENT INFORMATION SHEET 
Study Title:  To study the efficacy of thymus and activation-regulated chemokine 
(TARC) as a diagnostic marker of atopic dermatitis and its association with the 
severity of the disease in the paediatric age group in the Indian context 
 
We are inviting you to take part in a research study. Before you decide it is important 
for you to understand why we are doing the research and what it will involve. Please 
read the following information carefully and discuss it with others if you wish. Ask 
us if there is anything that is not clear or if you want more information. Take time to 
decide whether you wish to take part or no . 
 
Purpose of research: 
We are going to do a study on the relationship between a blood test, TARC, and atopic 
dermatitis and other skin conditions like seborrheic dermatitis, contact dermatitis, 
candidiasis, scabies and impetigo. There are different blood tests which correlate with 
the severity of atopic dermatitis. One of them, TARC, has been found to be the most 
specific for this. We want to do research on this topic because there is little 
information on this in India. This study will provide data on this topic and help for 
better understanding of markers of disease severity. This will be useful for optimum 
management of the disease. 
 
Expected duration of the Subject’s participation: 
You will be examined by the doctor only once in the study period. 
 
Description of the procedures: 
The doctor will do detailed examination and note down the information in a 
special form.  
Relevant blood investigations which include TARC, peripheral eosinophils, 
Immunoglobulin E(IgE) and lactate dehydrogenase(LDH) will be done depending on 
the clinical diagnosis and extent of disease. At the end of the study, we will analyse 
all the data obtained so far. 
 
Risks or discomforts to the Subject: 
Small amount of blood will be collected from peripheral vein. The most common 
side effects from blood drawing include: 
- Pain 
- Bleeding at the puncture site 
- Slight possibility of infection or fainting 
We are not doing any additional tests apart from the standard protocol 
 
Benefits to the Subject: 
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We are going to study the features of the disease and do tests like complete blood 
count, TARC, LDH, IgE. In this study we are going to know the association between 
TARC levels and various skin diseases and the severity of atopic dermatitis. This will 
be helpful in making a decision regarding treatment and the way in which the 
disease affects you. 
 
 
 
Benefits to others: 
Overall data about TARC levels and atopic dermatitis is very little in India. This 
study will provide data on this topic and help for better understanding of different 
clinical presentations of atopic dermatitis and its association with TARC. This will 
be useful for optimisation of duration of management of such conditions. 
 
Confidentiality: 
Your name and address will not be revealed at any point of time. All information 
which is collected about you during the course of the research will be kept strictly 
confidential unless we are required by law to share any information 
 
Participation: 
It is up to you to decide whether to take part or not. You are still free to withdraw 
from the study at any time, without giving any reason. A decision to withdraw, or a 
decision not to take part, will not affect the standard of care you receive. 
 
Contact person: 
Dr. Himadri, 
Post Graduate resident, 
Department of Dermatology, Venereology, Leprosy 
Christian Medical College, 
Vellore. 
Mobile- 9003237239 
Office-04162283527 
 118 
 
रोगी सूचना पत्र 
अध्ययन शीर्षक: एटॉपपक डर्मेटाइटटस से पीपित बच्चों (०-१६ वर्ष) के थाइर्मस एंड एपटटवेशन-रेगुलेटेड कीर्मोकाइन 
(TARC) का सीरर्म स्तर और बीर्मारी की गहनता से उसका सम्बन्ध  
हर्म आपको एक शोध अध्ययन र्में भाग लेने के पलए आर्मंपत्रत कर रहे हैं। इससे पहले कक आप कुछ तय कर सकें  आपके पलए 
यह सर्मझना र्महत्वपूर्ष ह ैकक हर्म यह शोध टयों कर रहे हैं, और इसर्में टया शापर्मल ककया गया ह।ै कृपया पनम्न जानकारी को 
ध्यानपूवषक पढ़ें और यकि आप चाहें तो िसुरे लोगों से भी इस पवर्य र्में चचाष करें। यकि इसर्में कुछ स्पष्ट नहीं ह ैअथवा इस बारे 
र्में आप अपधक जानकारी चाहते हैं तो हर्मसे पूछें। आप यह तय करने र्में सर्मय लें कक आप इसर्में पहस्सा लेना चाहते हैं या नहीं। 
शोध का उद्देश्य: हर्म एक रक्त परीक्षर्, TARC, और एटॉपपक डर्मेटाइटटस तथा अन्य त्वचा के रोग जैसे  सेबोटरक 
डर्मेटाइटटस, कांटेटट डर्मेटाइटटस, कैं पडपडआपसस, स्केबीज़ और रोिा के बीच संबंध पर एक अध्ययन करने जा रह ेहैं। 
पवपभन्न रक्त परीक्षर् एटॉपपक डर्मेटाइटटस की गहनता से सम्बंपधत हैं। उनर्मेंसे TARC सबसे अपधक पवपशष्ट पाया गया 
ह।ै भारत र्में इस पर कर्म जानकारी ह ैइसपलए हर्म इस पवर्य पर शोध करना चाहते हैं। इस अध्ययन से  इस पवर्य पर 
अपधक जानकारी प्राप्त होगी और रोग की गंभीरता के र्माकष र की बेहतर सर्मझ के पलए र्मिि पर्मलेगी। इससे रोग का बेहतर 
इलाज संभव होगा।  
रोगी की भागीिारी की अवपध: 
अध्ययन कल र्में पचककत्सक के द्वारा केवल एक बार आपकी जांच की जाएगी।   
प्रकियाओं का पववरर्: 
डॉटटर पवस्तृत शारीटरक पटरक्षर् करके सारी जानकारी को एक पत्र र्में पलखेंगे। पटरक्षर् नैिापनक  पनिान के आधार पर 
प्रासंपगक रक्त जांच जैसे TARC, इओपसनोकिल्स, इम्र्मुनोग्लोब्यूपलन इ (IgE) तथा लैटटेट डीहडै्रोजेन्स (LDH) 
पटरक्षर् ककये जायेंगे। अध्ययन के अंत र्में हर्म अब तक प्राप्त सभी डाटा का पवश्लेर्र् करके रोग की गंभीरता के साथ उसके 
सम्बन्ध का अध्ययन करेंगे। एटॉपपक डर्मेटाइटटस के अलावा जो र्मरीज़ अध्ययन र्में भाग लेंग,े TARC उनके पलए 
पनिःशुल्क ककया जायेगा।   
रोगी की असुपवधा तथा जोपखर्म: 
रक्त की थोिी सी र्मात्रा पटरधीय नस से एकत्र की जाएगी। खून पनकालने की संभापवत जटटलताएं पनम्नांककत हैं: 
- ििष 
- पंटचर के स्थान रक्त स्त्राव  
- इन्िेटशन या बेहोश होने की बहुत थोिी  सम्भावना 
हर्म र्मानक प्रोटोकॉल के अलावा कोई भी अपतटरक्त परीक्षर् नहीं कर रह ेहैं।  
रोगी को लाभ: 
हर्म इस त्वचा की बीर्मारी के पवपभन्न रूप तथा रक्त परीक्षर् जैसे पूर्ष रक्त प्रोिाइल, TARC, LDH, इज का 
अध्ययन करने जा रह ेहैं।  इस अध्ययन से हर्में TARC के सीरर्म स्तर तथा एटॉपपक डर्मेटाइटटस व अन्य त्वचा के रोगों 
की गहनता के बीच संभंध ज्ञात होगा।  इससे रोग की गंभीरता  का र्मागषिशषन करके उसके उपचार के बारे र्में िैसला लेने र्में 
र्मिि पर्मलेगी। 
िसूरों को लाभ: 
भारत र्में एटॉपपक डर्मेटाइटटस और TARC के बारे र्में बहुत कर्म जानकारी ह।ै यह अध्ययन इस पवर्य पर डाटा प्रिान 
करेगा पजससे एटॉपपक डर्मेटाइटटस के पवपभन्न लक्षर् तथा TARC से बीर्मारी की गहनता के सम्बन्ध को बेहतर तरीके से 
सर्मझने र्में र्मिि पर्मलेगी। इससे रोग के उत्तर्म उपचार के बारे र्में पनर्षय लेने र्में सहायता पर्मलेगी।  
गोपनीयता: 
ककसी भी सर्मय आपके नार्म और पते का खुलासा नहीं ककया जायेगा।  अनुसन्धान के िौरान जो भी जानकारी आपके द्वारा 
एकपत्रत की जाएगी उसे सख्ती से गोपनीय रखा जायेगा, जब तक की उस जानकारी को साझा करना कानून द्वारा आवश्यक 
न हो।  
भागीिारी: 
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यह तय करना आपके ऊपर पनभषर करता ह ैकक आप इसर्में पहस्सा लें या न लें। आप ककसी भी सर्मय पबना कोई कारर् बताये  
इस अध्ययन से अपनी भागीिारी वापपस ले सकते हैं। भाग न लेने का पनर्षय अथवा अपनी भागीिारी वापपस लेने का पनर्षय 
आपकी िखेभाल के र्मानक को प्रर्मापर्त नहीं करेगा।  
 
संपकष  करें: 
डॉ. पहर्माकि 
पोस्ट ग्रेजुएट रेपसडेन्ट 
त्वचा पवज्ञान, रपतजरोग, कुष्ठ रोग पवभाग 
किपस्चयन र्मेपडकल कॉलेज, 
वेल्लोर 
र्मोबाइल: 9003237239 
कायाषलय: 04162283527 
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பங்குபபறுபவர் தகவல் படிவம்: 
ஆய்வின் தலைப்பு: 
டி ஏ ஆர ்ஸி என்ற  கீம ோலைன் இரத்த அளலை, ஏட்மடோப்பிை் டடர ்லடடிஸ் உள்ள 
குழந்லதைளிை் ஆரோய்ந்து, அதற்கு ் மநோயின் தீவிரத்திற்கு ் உள்ள உறலையு ் 
குறித்து ஆரோய்தை். 
ஆய்வின்  ைோரண ்: 
நோங்ைள் தங்ைளுை்கு நோங்ைள் டெய்யு ் ஆரோய்ெச்ிலய பற்றி கூற 
விரு ்புகின்மறோ ். ஆரோய்ெச்ி என்பது ஒரு வியோதிலய குறித்து ம லு ் அறிந்து 
டைோள்ைதரை்்ைோன ஓர ்நை்ை ைழியோகு ். நோங்ைள் இப்மபோது ஏட்மடோப்பிை் 
டடர ்லடடிஸ் என்கின்ற வியோதிை்கு ் டிஏஆரஸ்ி என்கின்ற திரை ் இரத்தத்திை் 
இருப்பதற்கு ் உள்ள ெ ்பந்த்தத்லத அறிய விரு ்புகின்மரோ ். நோங்ைள் இந்த 
ஆய்விை் டெமபோரிை் டடர ்லடடிஸ், ைோன்டை்ட் டடர ்லடடிஸ், ைன்டீலடயோஸிஸ், 
ஸ்மைபிஸ், இ ்டபலடமைோ மபோன்ற மநோய்ைலளயு ் ஆய்வு டெய்கிமறோ ். தோங்ைள் 
எங்ைள் ஆரோய்ெச்ிை்கு உதவியோை இருப்பீரை்ள் என்று ைருதுகிமறோ ்.   
பங்கு டபறுபைரின் ஆய்வின் ைோை ்:  
இந்த ஆரய்ெச்ிை்ைோை ் முழுதிலு ் நோங்ைள் உங்ைலள ஒரு முலற டட்ும  ெந்திை்ை 
மதலை உண்டு. 
ஆய்வின் ைழிமுலற: 
 
இதற்ை்ைோை,  ருத்துைர ்தங்ைள் ெரு த்லத நன்றோை மெோதலன டெய்து 
ைண்டுபிடிப்புைலள ஒரு தனி தோளிை் எழுதுைோரை்ள். மதலை பட்டோை் மதோலிை் 
உள்ள புண்ைலள புலைப்பட ் பிடிப்போரை்ள். சிை ஆய்வுை்ைோை 
இரத்த ்  எடுை்ைப்படு ். இந்த ஆரய்ெச்ிை்ைோை ் முழுதிலு ் நோங்ைள் உங்ைலள ஒரு 
முலற டட்ும  ெந்திை்ை மதலை உண்டு. ஆனோலு ், தோங்ைள் விருப்பப்பட்டோை் 
எங்ைலள மீண்டு ் ைந்து ெந்திை்ை அனு தி உள்ளது. ஏட்மடோப்பிை் டடர ்லடடிஸ் 
இை்ைோத குழந்லதைளுை்கு டி ஏ ஆர ்ஸி ரத்த பரிமெோதலன இைைெ ோை 
டெய்யப்படு ்.  
 
ஆய்வினோை் உண்டோகு ் ெங்ைட ்: 
இரத்த ் எடுத்தைோை், சிறிது ைலி, இரத்தை் ைசிவு,  யை்ை ், ஆகியலை உண்டோை 
ைோய்ப்பு உள்ளது. 
 
ஆய்வினோை் மநோயோளிை்கு  உண்டோகு ் பயன்: 
இதன் மூை ோை தங்ைள் தினெரி ைோழ்ை்லையிை் பயன் இை்ைோவிட்டோலு ், இதன் 
மூை ோை கிலடை்கு ் டெய்திைலள பயன்படுத்தி நோங்ைள் தங்ைள் மநோலயை் 
குறித்து பை விஷயங்ைலள அறிந்து டைோள்ள முடியு ். அதன் ைோரண ோை இந்த 
வியோதியோை் சிர ப்படு ் டபோது ை்ைளுை்கு எங்ைளோை் உதை இயலு ். 
ஆய்வினோை் பிறருை்கு உண்டோகு ் பயன்: 
இந்த வியோதிலய பற்றி பை புதிய தைைை்ைலள அறிந்து டைோள்ளைோ ். அதன் 
ைோரண ோை இந்த வியோதியோை் சிர ப்படு ் பைருை்கு எங்ைளோை் உதை இயலு ். 
 
ஆய்வின் ந ்பைத்தன்ல : 
நீங்ைள் இந்த ஆரய்ெச்ியிை் பங்குடபற்றது குறித்து நோங்ைள் யோருை்கு ் டெோை்ை 
 ோட்மடோ ். ம லு ் இதிை் மெைறித்த விைரங்ைலள டைளியீடு டெய்யு ் மபோது 
தங்ைள் டபயலர இட ோட்மடோ ். 
 
தங்ைள் பங்ைளிப்பு: 
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இது முழுை்ை முழுை்ை தங்ைள் விருப்பத்துை்கு உற்ப்பட்டமத. தோங்ைள் எப்மபோது 
மைண்டு ோனலு ் பங்குடபற றுை்கு ் ைெதி உள்ளது. நீங்ைள் பங்குடபற 
 றுத்தோலு ் உங்ைள் லைத்தியத்திை் எந்த வித ோன மைறுபோடு ் ஏற்படோது. 
ஆய்ைோளர ்
டோை்டர.் ஹி ோத்ரி  
போலியை் ற்று ் டதோழு மநோய் பிரிவு - 1 
கிறிஸ்த்துை ருத்துைை் ைை்லூரி 
மைலூர ்            
04162283527 
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ANNEXURE-2 : PROFORMA 
Serial No.    Date:     Hospital No. 
Name:     Age:     Sex: M/F 
Address:        Contact no. 
Diagnosis: Atopic dermatitis/ seborrheic dermatitis/ contact dermatitis/ candidiasis/ scabies/ 
impetigo 
 
History of atopic dermatitis 
Natal history: Mode of delivery: Vaginal/ Caesarean 
Birth order:   Duration of exclusive breastfeeding: ____ months 
Age of onset: ___ months  
Site of onset: 
Sites involved: Face/ Neck/ upper limbs- flexor; extensor/ Lower limbs-flexor; extensor/ Trunk/ 
Scalp/ Mucosa/ Nails/ Hair 
Dry skin: 
Seasonal variation: Yes/No; if yes, Winter/Summer/Rainy season/Autumn/Spring 
No. of exacerbations/year: 
Personal history of atopy: Asthma/ Allergic rhinitis/ Allergic conjunctivitis 
Triggers: Stress/ Skin infections/ Food allergens/ Airborne allergens/ Sweating/ Excessive heat/ 
Winter/ Wool clothing/ Irritants/ Habitual scratching/ Others 
Exposure to pets: Dog/ Cat/ Others ___________________________ 
Relieving factors: 
Sleep disturbance: 
Behavioural changes: 
Complications: Skin infection: Bacterial/Eczema herpeticum/ Eczema vaccinatum 
 Documented pus culture: 
 Systemic infections: Bacteremia/Respiratory/Others 
Treatment history: 
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 Non dermatological: 
Dermatological: 
Drug Duration of treatment Last taken on 
Emollients   
Topical steroids   
Topical calcineurin inhibitors   
Antihistamines   
Systemic steroids   
Antibiotics   
Cyclosporine   
Azathioprine   
Methotrexate   
Phototherapy   
Biologicals   
Others   
 
Family history of atopy: Yes/No  If yes : Asthma/ Allergic rhinitis/ Allergic conjunctivitis 
  1st degree/2nd degree/3rd degree 
Examination: 
Height-             cm   (centile-              )                               Weight-           kg (centile-              ) 
Significant lymph nodes: Cervical/ Axillary/ Inguinal 
Ocular changes: Keratoconjunctivitis/ Keratoconus/ Cataract/ Others/ Nil 
Dennie-Morgan folds: Present/Absent 
Sites involved: Face/ Neck/ upper limbs- flexor-cubital fossa/axilla; extensor/ Lower limbs-flexor-
popliteal fossa; extensor/ Trunk/ Scalp/ Mucosa/ Nails/ Hair 
Type of lesion: Eczema/ Prurigo/ Psoriasiform/ Excoriation/ Xerosis/ Secondary infection/ 
Lichenification / Keratosis pilaris/ Palmar hyperlinearity/Others 
SCORAD: Objective: ________  Subjective: ________  Total: ______ 
Investigations: 
Serum TARC: 
Peripheral eosinophils (%): 
Serum Lactate dehydrogenase (units/L): 
Immunoglobulin E (units/mL): 
Quality of life: 
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IDQOL: _______    Dermatitis severity: _______ 
CDLQI: _______ 
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ANNEXURE-3: SCORAD 
SCORAD (SCORing Atopic Dermatitis) Index: 
 
Area Percentage affected 
Head and neck   
Upper limbs   
Lower limbs   
Anterior trunk   
Back   
Genitals   
Total (A)  
 
Intensity: A representative area of eczema is selected and the intensity of each of the 
following signs is assessed as none (0), mild (1), moderate (2) or severe (3). 
  Intensity score 
Redness  
Swelling  
Oozing / crusting  
Skin thickening (lichenification)  
Scratch marks  
Dryness (assessed in an area without 
inflammation)  
 
Total (B) (maximum 18)  
 
Subjective symptoms:  
 Score 
No itch (0) to worst imaginable itch (10)   
No sleeplessness (0) to worst imaginable 
sleeplessness (10) 
 
Total (C)  
 
  
Total score: A/5 + 7B/2 + C = 
 
 
Objective SCORAD was graded as mild (<15), moderate (15-40) and severe (>40). 
SCORAD index which included the objective and subjective scores was graded as 
mild (<25), moderate (25-50) and severe (>50).  
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ANNEXURE-4: SERUM TARC LEVEL DETERMINATION 
Serum TARC levels were determined by using enzyme- linked immunosorbent assay 
(Abcam’s TARC Human ELISA kit) 
PRINCIPLE: 
This assay employs an antibody that is specific for Human TARC and is coated on a 
96-well plate. Standards as well as samples are pipetted into the wells. TARC gets 
bound to the wells by the immobilized antibody. The wells are washed and 
biotinylated anti-Human TARC antibody is added. After washing away unbound 
biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells 
are again washed, a TMB substrate solution is added to the wells and colour develops 
in proportion to the amount of TARC bound. The Stop Solution changes the colour 
from blue to yellow, and the intensity of the colour is measured at 450 nm. 
SAMPLING AND STORAGE: 
Serum is separated from blood sample collected by venepuncture and stored at -
2 °0 C .The kit is also stored at -20°C. 
REAGENTS: 
20X Wash Buffer Concentrate 
Recombinant Human TARC Standard 
Assay Diluent C 
5X Assay Diluent B 
Biotinylated anti-human TARC 
400X HRP-Streptavidin Concentrate 
TMB One-Step Substrate reagent 
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Stop Solution 
REAGENT PREPARATION: 
All reagents are equilibrated to room temperature (18-25°C) prior to use. 
1X Assay Diluent B: 
5X Assay Diluent B is diluted 5-fold with deionized or distilled water. 
1X Wash Solution: 
20mL of 20X Wash Buffer Concentrate is diluted with deionized or distilled water to 
yield 400mL of 1X Wash Buffer. 
1X Biotinylated TARC Detection Antibody: 
100μL of 1X Assay Diluent B is added into the vial to prepare a detection antibody 
concentrate. The detection antibody concentrate is diluted 80-fold with 1X Assay 
Diluent B prior to use. 
1X HRP-Streptavidin Solution: 
HRP-Streptavidin concentrate is diluted 400-fold with 1X Assay Diluent B prior to 
use. 
STANDARD PREPARATION: 
50ng/mL of Stock Standard is prepared by adding 400μL of Assay Diluent C into the 
vial of TARC Standard. 
Standard #1 is prepared by adding 30μL of 50ng/mL Stock Standard to 570μL of 
Assay Diluent C into tube #1. 300μL of Assay Diluent C is pipetted into the remining 
tubes. 
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Standard #2 is prepared by adding 200μL Standard #1 to tube #2 and so on as given 
below: 
Standard # Volume to 
dilute (μL) 
Diluent 
(μL) 
Total 
Volume 
(μL) 
Starting 
Conc. 
(pg/mL) 
Final Conc. 
(pg/mL) 
1 30 570 600 50,000 2,500 
2 200 300 500 2,500 1,000 
3 200 300 500 1,000 400 
4 200 300 500 400 160 
5 200 300 500 160 64 
6 200 300 500 64 25.6 
7 200 300 500 25.6 10.2 
8 0 300 300 0 0 
 
SAMPLE PREPARATION: 
Assay Diluent C should be used for dilution of serum, the optimal dilution factor 
being determined by the investigator.  
PROCEDURE: 
1. 100μL of each standard and sample is added into appropriate wells, and then 
incubated for 2.5 hours at room temperature or overnight at 4°C with gentle 
shaking.  
2. The solution is discarded and washed 4 times with 1X Wash Solution. 
3. 100μL of 1X Biotinylated TARC Detection Antibody is added to each well 
and incubated for 1 hour at room temperature with gentle shaking.  
4. The solution is discarded and washed as in step 2. 
5. 100μL of 1X HRP-Streptavidin solution is added to each well and incubated 
for 45 minutes at room temperature with gentle shaking. 
6. The solution is discarded and washed as in step 2. 
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7. 100μL of TMB One-Step Substrate Reagent is added to each well and 
incubated for 30 minutes at room temperature in the dark with gentle shaking. 
8. 50μL of Stop Solution is added to each well and reading is done at 450nm. 
CALCULATIONS: 
The results are calculated by a microplate reader, capable of measuring absorbance 
at 450nm. 
SENSITIVITY: 
The minimum detectable dose of TARC was less than 5 pg/mL. 
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ANNEXURE-5 : CDLQI & IDQOL 
   CHILDREN'S DERMATOLOGY LIFE QUALITY INDEX 
Hospital No 
Name:     Diagnosis:    CDLQI  
Age:          SCORE: 
Address:    Date:  
 
The aim of this questionnaire is to measure how much your skin problem has 
affected you OVER THE LAST WEEK.  Please tick ✓ one box for each question. 
 
1. Over the last week, how itchy, "scratchy",                  Very much  □ 
 sore or painful has your skin been?                   Quite a lot  □ 
           Only a little  □ 
          Not at all  □ 
 
2. Over the last week, how embarrassed                 Very much  □ 
 or self conscious, upset or sad have you                  Quite a lot  □ 
 been because of your skin?       Only a little  □ 
          Not at all  □ 
 
3. Over the last week, how much has your                  Very much  □ 
 skin affected your friendships?                   Quite a lot  □ 
          Only a little  □ 
          Not at all  □ 
 
4. Over the last week, how much have you changed                Very much  □ 
 or worn different or special clothes/shoes                 Quite a lot  □ 
 because of your skin?                   Only a little  □ 
          Not at all  □ 
 
5. Over the last week, how much has your                 Very much  □ 
 skin trouble affected going out, playing,                 Quite a lot  □ 
 or doing hobbies?       Only a little  □ 
          Not at all  □ 
 
6. Over the last week, how much have you               Very much  □ 
 avoided swimming or other sports because                              Quite a lot  □ 
 of your skin trouble?       Only a little  □ 
          Not at all  □ 
 
7. Last week,    If school time: Over the             Prevented school               □    
              last week, how much did                 Very much  □ 
 school time?                your skin problem affect your              Quite a lot  □ 
     school work?    Only a little  □ 
    OR         Not at all  □ 
 
 was it      If holiday time: How much  Very much  □ 
 holiday time?                    over the last week, has your  Quite a lot  □ 
     skin problem interfered with  Only a little  □ 
     your enjoyment of the holiday?               Not at all  □ 
 
8. Over the last week, how much trouble                  Very much  □ 
 have you had because of your skin with                 Quite a lot  □ 
 other people calling you names, teasing,                Only a little  □ 
 bullying, asking questions or avoiding you?                Not at all  □ 
 
9. Over the last week, how much has your sleep                 Very much  □ 
 been affected by your skin problem?                  Quite a lot  □ 
was it 
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          Only a little  □ 
          Not at all  □ 
 
10. Over the last week, how much of a                    Very much  □ 
 problem has the treatment for your                   Quite a lot  □ 
 skin been?        Only a little  □ 
           Not at all  □ 
Please check that you have answered EVERY question. Thank you.  
 
Â© Childrenâ€™s Dermatology Life Quality Index. M.S.Lewis-Jones, AY Finlay, May 1993. 
www.dermatology.org.u 
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बाल त्वचारोग जीवन गुणवत्ता सूची 
हॉस्पिटल क्रमाांक: 
नाम :    रोग ननदान:   सीएलडीक्यूआई पकोर   
उम्र:    ददनाांक: 
िता: 
इस प्रश्नोत्तरी का उद्देश्य यह नािना है कक आिकी त्वचा की िरेशानी ने गत सप्ताह में आिके जीवन िर ककतना प्रभाव 
डाला है।  कृिया हर प्रश्न के ललए एक बॉक्स िर दटक करें। 
 
1. गत सप्ताह, आिकी त्वचा में ककतनी खुजली, िीड़ा, ददद या चुभन लग रहा था?     बहुत ज़्यादा  □ 
                        बहुत   □ 
           थोड़ा   □ 
          बबलकुल नहीां  □ 
 
2. गत सप्ताह, अिनी त्वचा के कारण आिन ेककतने शमदसार, पव चैतन्य         बहुत ज़्यादा  □ 
                        बहुत   □ 
           थोड़ा   □ 
          बबलकुल नहीां  □ 
 
3. गत सप्ताह, आिकी त्वचा ने आिकी दोपती िर ककतना प्रभाव डाला? बहुत ज़्यादा  □ 
                        बहुत   □ 
           थोड़ा   □ 
          बबलकुल नहीां  □ 
 
4. गत सप्ताह, आिकी त्वचा ने आिके किड़/ेजूत ेिहनने िर ककतना प्रभाव डाला? बहुत ज़्यादा  □ 
                        बहुत   □ 
           थोड़ा   □ 
          बबलकुल नहीां  □ 
 
5. गत सप्ताह, आिकी त्वचा ने आिके सामास्जक जीवन या फुरसत के समय         बहुत ज़्यादा  □ 
 की गनतववधियों या खेलकूद िर ककतना प्रभाव डाला?           बहुत  □ 
          थोड़ा   □ 
          बबलकुल नहीां  □ 
 
6. गत सप्ताह, आिकी त्वचा ने तैराकी या आिके अन्य खेलकूद के ललए बहुत ज़्यादा  □ 
 ककतनी मुस्श्कलें खड़ी कीां?                                 बहुत   □ 
          थोड़ा   □ 
          बबलकुल नहीां  □ 
 
7. गत सप्ताह,    यदद ववद्यालय का समय:             ववद्यालय जाने से रोका    □    
          गत सप्ताह, आिकी त्वचा ने               बहुत ज़्यादा  □ 
                 आिकी िढाई में ककतनी               बहुत   □ 
     रूकावट डाली?    थोड़ा   □ 
          बबलकुल नहीां  □ 
                   या 
 क्या छुट्टी का      यदद छुट्टी का समय: गत सप्ताह,   बहुत ज़्यादा  □ 
 समय था?                    आिकी त्वचा ने आिकी छुट्टी  बहुत   □ 
     का आनन्द लेने िर ककतना प्रभाव  थोड़ा   □ 
     डाला?                  बबलकुल नहीां  □ 
 
8. गत सप्ताह, क्या आिकी त्वचा की वजह से लोगों ने            बहुत ज़्यादा  □ 
 आिको धचढ़ाया, मज़ाक उड़ाया, प्रश्न ककये या आिसे             बहुत  □ 
 िरहेज ककया?                   थोड़ा  □ 
          बबलकुल नहीां  □ 
 
9. गत सप्ताह, क्या आिकी त्वचा ने आिकी नीांद िर ककतना प्रभाव डाला?              बहुत ज़्यादा □ 
                        बहुत   □ 
           थोड़ा   □ 
क्या ववद्यलाय 
का समय था 
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          बबलकुल नहीां  □ 
 
10. गत सप्ताह, आिकी त्वचा के उिचार ने आिके ललए ककतनी मुस्श्कलें खड़ी कीां? बहुत ज़्यादा □ 
                        बहुत   □ 
           थोड़ा   □ 
          बबलकुल नहीां  □ 
कृिया देख लें कक आिन ेहर प्रश्न का उत्तर दे ददया है। िन्यवाद। 
Children’s Dermatology Life Quality Index © M.S.Lewis-Jones, AY Finlay, May 1993. www.dermatology.org.uk 
 
 137 
 
 
 138 
 
 
 139 
 
 
 140 
 
 
 141 
 
 
 142 
 
 143 
 
 
  
    INFANTS’ DERMATITIS QUALITY OF LIFE INDEX (IDQOL) 
 
Name:     Date:    IDQOL 
Address:        SCORE 
 
 
The aim of this chart is to record how your child’s dermatitis has been.  Each question concerns THE LAST 
WEEK ONLY.  Please could you answer every question. 
 
Dermatitis Severity 
 Over the last week, how severe do you   Extremely severe  
 think your child’s dermatitis has been?;   Severe    
 i.e. how red, scaly, inflamed or widespread.   Average   
         Fairly good   
         None    
Life Quality Index 
1. Over the last week, how much has your   All the time   
 child been itching and scratching?    A lot    
         A little    
         None    
 
2. Over the last week, what has your child’s   Always crying, 
 mood been?       extremely difficult  
         Very fretful   
         Slightly fretful   
         Happy    
 
3. Over the last week approximately how    More than 2 hrs  
 much time on average has it taken to    1 - 2 hrs   
 get your child off to sleep each night?   15mins - 1 hr   
         0-15mins   
 
4. Over the last week, what was the total   5 hrs or more   
 time that your child’s sleep was disturbed   3 - 4 hrs   
 on average each night?      1 - 2 hrs   
         Less than 1 hour  
 
5. Over the last week, has your child’s eczema   Very much   
 interfered with playing or swimming?   A lot    
         A little    
         Not at all   
 
6. Over the last week, has your child’s eczema   Very much   
 interfered with your child taking part in or   A lot    
 enjoying other family activities?    A little    
         Not at all   
 
7. Over the last week, have there been    Very much   
 problems with your child at mealtimes   A lot    
 because of the eczema?     A little    
         None    
 
8. Over the last week, have there been problems   Very much   
 with your child caused by the treatment?   A lot    
         A little    
         None    
 
9. Over the last week, has your child’s eczema   Very much   
 meant that dressing and undressing the   A lot    
 child has been uncomfortable?    A little    
         None    
 
10. Over the last week how much has your child   Very much   
 having eczema been a problem at bathtime?   A lot    
         A little    
         None    
 
Please can you check that you have answered every question. 
© M.S. Lewis-Jones, A.Y. Finlay Jan 2000 
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हॉस्पिटल क्रमाांक: 
नाम :    रोग ननदान:     आईडीक्यू लएल पकोर   
उम्र:    ददनाांक: 
िता: 
इस प्रश्नोत्तरी का उद्देश्य यह नािना है कक आिके लशशु की त्वचा की िरेशानी ने गत सप्ताह में ककतना प्रभाव डाला है।  कृिया हर 
प्रश्न के ललए एक बॉक्स िर दटक करें। 
डम टाइदटस की गहनता 
 गत सप्ताह आिके अनुसार आिके लशशु की त्वचा   बहुत ज़्यादा   
 की बीमारी ककतनी गांभीर थी? जैसे, ककतना    ज़्यादा    
 लालिन, चमड़ा ननकलना, सूजन या फैला हुआ?   म यम    
         का ी अ छा   
         बबलकुल नहीां   
जीवन की गुणवत्ता सूचकाांक 
1. गत सप्ताह, आिका लशशु ककतनी खुस्ज कर रहा/रही है?       हर समय  □ 
         बहुत   □ 
          थोड़ा   □ 
         बबलकुल नहीां  □ 
 
2. गत सप्ताह, आिका लशशु की मनोदशा कैसी है?   हमेशा रो रहा/रही है, 
          बहुत ही मुस्श्कल   
         बहुत धचड़धचड़ा   
         थोड़ा धचड़धचड़ा   
         खुश    
 
3. गत सप्ताह, आिका लशशु को सुलाने में लगभग ककतना समय लगा?     ांटे से ज़्यादा   
          -   ांटे    
            लमनट-   ांटा   
           -   लमनट   
 
4. गत सप्ताह, हर रात लगभग ककतनी देर आिके लशशु की नीांद    ांटे या ज़्यादा   
  राब हुई?       3-   ांटे   
           -   ांटे    
            ांटे से कम   
 
5. गत सप्ताह, क्या त्वचा की बीमारी के कारण आिके ब च ेके  बहुत ज़्यादा   
 खेलने या तैराकी िर प्रभाव िड़ा?     बहुत   □ 
          थोड़ा   □ 
         बबलकुल नहीां  □ 
 
6. गत सप्ताह, क्या त्वचा की बीमारी के कारण आिके ब च ेके  बहुत ज़्यादा   
 अन्य िा रवा रक कायदक्रमों में भाग लेने िर प्रभाव िड़ा?  बहुत   □ 
          थोड़ा   □ 
         बबलकुल नहीां  □ 
 
7. गत सप्ताह, क्या त्वचा की बीमारी के कारण आिके ब च ेके  बहुत ज़्यादा   
 भोजन िर प्रभाव िड़ा?      बहुत   □ 
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          थोड़ा   □ 
         बबलकुल नहीां  □ 
 
8. गत सप्ताह, क्या त्वचा की बीमारी के उिचार के कारण कुछ  बहुत ज़्यादा   
 मुस्श्कलें आ ?       बहुत   □ 
          थोड़ा   □ 
         बबलकुल नहीां  □ 
 
9. गत सप्ताह, क्या त्वचा की बीमारी के कारण ब च ेको  बहुत ज़्यादा   
 किड़ ेिहनाने या उतारने में मुस्श्कलें आ ?    बहुत   □ 
          थोड़ा   □ 
         बबलकुल नहीां  □ 
 
10. गत सप्ताह, त्वचा की बीमारी के कारण ब च ेको   बहुत ज़्यादा   
 नहलाने में ककतनी मुस्श्कलें आ ?     बहुत   □ 
          थोड़ा   □ 
         बबलकुल नहीां  □ 
 
कृिया देख लें कक आिन ेहर प्रश्न का उत्तर दे ददया है। िन्यवाद। 
© M.S. Lewis-Jones, A.Y. Finlay Jan 2000 
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குழந்தைகள் சரும வாழ்வுத் ைரம் அட்டவதை   
 
மருத்துவமலன எண்:     கபயர்: 
வயது:      முெவரி:  
கததி:       ட ாய்:  
மதிப்கபண்: 
 
இந்த டெள்வித்தாளின் குறிக்டொள் உங்ெள் குழந்லதயின் சரும ட ாய் உங்ெள் 
குழந்லதயின் வாழ்க்லெலய ெெந்த வாரத்தில் எந்த அளவிற்கு பாதித்துள்ளது 
என்பலத அளவிடுவதாகும். ஒவ்கவாரு டெள்விக்கும் ஒவ்கவாரு ெட்ெத்லத 
ெண்டீப்பாெத் டதர்வு கசய்யவும்.   
 
டடர்மதடடிஸ் ைவீிரம்:   
ெெந்த வாரத்தில் , உங்ெள் குழந்லதயின் கெர்மலெடிஸ்  கவகு தீவிரமாெ  
  
 எவ்வளவு தீவிரமாெ இருந்தது ?      மிெ தீவிரமாெ  
            
 சாதார்ணமாெ    
           குலறவாெ  
   
          இல்ைடவ 
இல்லை    
             
 வாழ்க்தக ைர அட்டவதை:  
1. ெெந்த வாரத்தில் , உங்ெள் குழந்லத எவ்வளவு    ீண்ெ ட ரம்     
ட ரம் அரிப்பாலும் கசாறியாலும் டவதலன பட்ொன்?  குலறந்த ட ரம்  
            
 அரிக்ெடவ இல்லை          
     இல்ைடவ இல்லை    
2.ெெந்த வாரத்தில் உங்ெள்    எப்டபாதும் அழுதுகொண்கெ இருந்தான்  
  
  குழந்லத எப்படி இருந்தான்?  சண்லெ டபாட்டுக்கொண்டெ 
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இருந்தான்    
        மிெவும் வருந்திக்கொண்டெ 
இருந்தான்    
        சிறிது ட ரம் வருந்திக்கொண்டு 
இருந்தான்   
        மெிழ்ச்சியாெ இருந்தான்   
   
 
3. ெெந்த வாரத்தில் , குழந்லதலய தூங்ெ   2 மணி ட ரத்துக்கு டமல்   
  
    லவக்ெ எவ்வளவு ட ரம் ஆனது ?  1-2 மணி ட ரங்ெள்      
         15 ிமிெங்ெளிைிருந்து 1 மணி 
ட ரம்   
        15 ிமிெங்ெள் வலர    
 
4. ெெந்த வாரத்தில் , உங்ெள் குழந்லதயின் தூக்ெம்  5 மணி ட ரம்     
   எவ்வளவு ட ரம் பாதிக்ெப்பட்டிருந்தது ?   3-4 மணி ட ரம்     
          1-2 மணி ட ரம்   
  
          ஒரு மணி 
ட ரத்திற்கும் ெீழ்   
5. ெெந்த வாரத்தில் , உங்ெள் குழந்லத விலளயாடுவடதா   மிகுந்த 
அளவில்  
   ீந்துவடதா, ட ாயினால் பாதிக்ெப்பட்டுள்ளதா ?     கராம்ப 
            
  குலறந்த அளவில்         
      இல்ைடவ இல்லை   
6. ெெந்த வாரத்தில் உங்ெள் குழந்லத குடும்ப  ிெழ்வுெளில்   மிகுந்த 
அளவில்  பங்குகபறுதல் பாதிக்ெப்பட்டுள்ளதா?     
 கராம்ப          
     குலறந்த அளவில்      
         இல்ைடவ இல்லை   
7. ெெந்த வாரத்தில் உங்ெள் குழந்லத உணவு உண்பது ,   மிகுந்த அளவில்   
   ட ாயினால் பாதிக்ெப்பட்டுள்ளதா?     கராம்ப 
            
  குலறந்த அளவில்         
      இல்ைடவ இல்லை   
8. ெெந்த வாரத்தில் , ட ாய் சிெிச்லசயின் ொரணத்தால்   மிகுந்த அளவில்  
   குழந்லதக்கு ஏடதனும் ெஷ்ெம் உண்ொெியிருந்ததா ?  
 கராம்ப          
     குலறந்த அளவில்      
         இல்ைடவ இல்லை   
 148 
 
9. ெெந்த வாரத்தில் குழந்லதயின் ட ாய் ொரணமாெ ,    மிகுந்த 
அளவில்     துணி டபாடுவதும் ெளற்றுவதும் சிரமமாெ 
இருந்ததா?   கராம்ப        
       குலறந்த அளவில்    
          
 இல்ைடவ இல்லை   
10. ெெந்த வாரத்தில் , உங்ெள் குழந்லதயின் ட ாய்    மிகுந்த 
அளவில்     குளிப்பதற்கு சிரமம் கொடுத்ததா?   
  கராம்ப         
      குலறந்த அளவில்     
          இல்ைடவ 
இல்லை  
மீண்டும் ஒரு முலற அலனத்து டெள்விெளுக்கும் பதில் அளித்துள்டளாமா 
என்பலத சரிபார்த்துக் கொள்ளவும்.  
© M.S. Lewis-Jones, A.Y. Finlay Jan 2000 
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ANNEXURE-6: IRB APPROVAL 
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ANNEXURE-7 : CODES TO MASTER CHART 
sno        serial number        <IDNUM> 
name       name                 ______________________________ 
hospno     hospital number      _______ 
age        age                  ##.## 
sex        sex                  # 1 male 2 female     
add        address              # 1 Tamil Nadu  2  Kerala  3 Karnataka  4 Andhar 
Pradesh/Telangana  5 West Bengal  6 Bangladesh 7 Bihar 8 Jharkhand  9 Others 
add7       if other places, specify _____________________ 
diag       diagnosis            # 1 atopic dermatitis    2 seborrheic dermatitis    
3 contact dermatitis    4 candidiasis    5 scabies    6 impetigo    7 psoriasis  
   
AD         atopic dermatitis    # 1 yes   2 no 
delmod     mode of delivery         # 1 vaginal 2 Caesarean 
bo         birth order           # 
ebf        duration of exclusive breastfeeding  ##.# 
onsetage   age of onset         ###.## 
site of onset        
    fc    face                 # 1 yes   2 no 
    nk    neck                 # 1 yes   2 no 
    ulf   upperlimb flexor     # 1 yes   2 no 
    ule   upperlimb extensor   # 1 yes   2 no 
    llf  lowerlimb flexor      # 1 yes   2 no 
    lle  lowerlimb extensor    # 1 yes   2 no 
    tk    trunk                # 1 yes   2 no 
    sp    scalp                # 1 yes   2 no 
    muc   mucosa               # 1 yes   2 no 
         
sites involved 
    face   face               # 1 yes   2 no 
    neck   neck               # 1 yes   2 no 
    ulfl upperlimb flexor     # 1 yes   2 no 
    ulex upperlimb extensor   # 1 yes   2 no 
    LLfl lowerlimb flexor     # 1 yes   2 no 
    LLex lowerlimb extensor   # 1 yes   2 no 
    trunk  trunk              # 1 yes   2 no 
    scalp  scalp              # 1 yes   2 no 
    mucosa  mucosa            # 1 yes   2 no 
    nails   nails             # 1 yes   2 no 
    hair    hair              # 1 yes   2 no 
 
dryskin   dry skin            # 1 yes   2 no 
 
seasonvar    seasonal variation    # 1 yes   2 no 
win    winter    # 1 yes   2 no 
sum    summer    # 1 yes   2 no 
rain   rainy     # 1 yes   2 no 
aut    autumn    # 1 yes   2 no 
spr    spring    # 1 yes   2 no 
 
freq    number of exacerbations per year    ## 
 
atopy    personal history of atopy    # 1 yes   2 no 
    BA    asthma                      # 1 yes   2 no 
    AR    allergic rhinitis           # 1 yes   2 no 
    AC    allergic conjunctivitis     # 1 yes   2 no 
Triggers 
stress                              # 1 yes   2 no 
skininf    skin infections          # 1 yes   2 no 
food       food allergens           # 1 yes   2 no 
air        airborne allergens       # 1 yes   2 no 
sweat      sweating                 # 1 yes   2 no 
heat       excessive sweating       # 1 yes   2 no 
winter     winter                   # 1 yes   2 no 
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wool       wool clothing            # 1 yes   2 no 
irritants  irritants                # 1 yes   2 no 
scratch    habitual scratching      # 1 yes   2 no 
others     miscellaneous            # 1 yes   2 no 
ifothers   if others yes ______________________________ 
 
relief    relieving factors    __________________________________________________ 
expet     exposure to pets     # 1 yes   2 no  
dog       exposure to dogs     # 1 yes   2 no 
cat       exposure to cats     # 1 yes   2 no 
petoth    other pets           # 1 yes   2 no 
pettype   if other pets, specify ___________________________ 
sleep     sleep disturbance    # 1 yes   2 no 
behave    behavioural changes  # 1 yes   2 no 
complications 
inf       skin infection       # 1 yes   2 no 
inf_freq  single or recurrent infection     # 1 single  2 recurrent 
bact      bacterial            # 1 yes   2 no 
pus       documented pus culture # 1 yes   2 no 
pusorg    if pus culture done, organism    ______________________________ 
eczher    eczema herpeticum    # 1 yes   2 no 
eczvac    eczema vaccinatum    # 1 yes   2 no 
sysinf    systemic infections  # 1 yes   2 no 
bacteremia    bacteremia    # 1 yes   2 no 
respi         respiratory   # 1 yes   2 no 
misc        others          # 1 yes   2 no 
ifmisc    if others, yes    _______________ 
Treatment 
nonderm    non dermatological ______________________________ 
derm       dermatological                          # 1 yes   2 no 
emol       emollients                              # 1 yes   2 no 
topster    topical steroids                        # 1 yes   2 no 
topcalinh    topical calcineurin inhibitors        # 1 yes   2 no 
antihis    antihistamines used                     # 1 yes   2 no 
sysster    systemic steroids                       # 1 yes   2 no 
antibiot    antibiotics used                       # 1 yes   2 no 
cyclospo    cyclcosporine used                     # 1 yes   2 no               
azathio       azathioprine used                    # 1 yes   2 no 
mtx           methotrexate used                    # 1 yes   2 no               
photo        phototherapy used                     # 1 yes   2 no 
bio          biologicals used                      # 1 yes   2 no 
oth          other treatment used                  # 1 yes   2 no 
othwhat      if other therapy used, specify ____________________ 
 
famatopy    family history of atopy             # 1 yes   2 no 
fam_BA      family history of asthma            # 1 yes   2 no 
fam_BAdeg   degree of relative with asthma      # 
fam_AR      family history of allergic rhinitis # 1 yes   2 no 
fam_ARdeg   degree of relative with allergic rhinitis    # 
fam_AC      family history of allergic conjunctivitis    # 1 yes   2 no 
fam_ACdeg   degree of relative with allergic conjunctivitis   # 
 
EXAMINATION 
htcent        height in centile      ###.# 
wtcent        weight in centile      ###.# 
cerLN         cervical lymphadenopathy    # 1 yes   2 no 
axLN          axillary lymphadenopathy    # 1 yes   2 no 
ingLN         inguinal lymphadenopathy    # 1 yes   2 no 
kerconj       keratoconjunctivitis        # 1 yes   2 no 
kerconus      keratoconus                 # 1 yes   2 no 
cataract      cataract                    # 1 yes   2 no 
ophmisc       others ophthal findings     ______________________________ 
denmor        dennie morgan folds         # 1 yes   2 no 
eczema        eczema                      # 1 yes   2 no 
face_E        eczema on face              # 1 yes   2 no 
neck_E        eczema on neck              # 1 yes   2 no 
ulflc_E       eczema on cubital fossa     # 1 yes   2 no 
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ulfla_E       eczema on axilla     # 1 yes   2 no 
ulexy_E    eczema on extensor aspect of upper limbs # 1 yes   2 no 
llfly_E    eczema on flexor aspect of lower limbs   # 1 yes   2 no  
llext_E    eczema of extensor aspect of lower limbs # 1 yes   2 no 
trunky_E   eczema on trunk                          # 1 yes   2 no 
 
lichen     lichenification seen                     # 1 yes   2 no 
facey   face                       # 1 yes   2 no 
necky   lichenification on neck              # 1 yes   2 no 
ulflc upperlimb flexor cubital fossa         # 1 yes   2 no 
ulfla upperlimb flexor axillae               # 1 yes   2 no 
ULexy upperlimb extensor                     # 1 yes   2 no 
LLfly lowerlimb flexor popliteal fossa       # 1 yes   2 no 
LLexy lowerlimb extensor          # 1 yes   2 no 
trunky lichenification on trunk              # 1 yes   2 no 
 
other sites involved 
scalpy  scalp              # 1 yes   2 no 
mucosay  mucosa            # 1 yes   2 no 
nailsy  nails              # 1 yes   2 no 
hairy   hair               # 1 yes   2 no 
 
prurigo   prurigo              # 1 yes   2 no 
pr_site   sites with prurigo lesions _______________________________ 
psor      psoriasiform         # 1 yes   2 no 
psor_site sites with psoriasiform lesions ___________________________ 
excor     excoriation          # 1 yes   2 no 
xeros     xerosis              # 1 yes   2 no 
secinf    secondary infections # 1 yes   2 no 
pusexam   organism on pus culture ___________________________________ 
kp        keratosis pilaris     # 1 yes   2 no 
palmhyper palmar hyperlinearity # 1 yes   2 no 
iv        ichthyosis vulgaris   # 1 yes   2 no  
examother other skin lesions    
____________________________________________________________________________ 
 
SCORobj    Objective SCORAD    ##.# 
SCORsub    Subjective SCORAD   ##.# 
TIS        SCORAD index        ##.# 
 
Investigations: 
TARC       TARC in pg/ml       ####.## 
eos        Eosinophils in %    ## 
LDH        LDH in units/L      #### 
IgE        IgE in units/ml     #####.# 
vitD     Vitamin D in ng/mL  ##.# 
ns_cul     Nasal culture done             # 1 yes   2 no  
ns_org     Organism on nasal culture __________________________ 
immunoblot Atopy immunoblot done          # 1 yes   2 no 
food_imm   Positive to food on immunoblot 
foodname   Name of food to which strongly positive________________________ 
foodweak   Name of food to which weakly positive__________________________ 
dustmite   Postive immunoblot to dust mite    # 1 yes   2 no 
otherimmuno Any other agents with positive immunoblot ____________________ 
 
IDQOL4     AD child upto 4 years  # 1 yes   2 no 
IDQOL      total IDQOL score    ## 
dermsever    dermatitis severity score # 
CDLQI      total CDLQI score    ## 
 
N.A.      Not applicable 
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